The domain within your query sequence starts at position 9 and ends at position 45; the E-value for the S_TKc domain shown below is 3e-14.
WARNING!
Some of the required catalytic sites were not detected in this domain. It is probably inactive! Check the literature (PubMed 7768349 ) for details.
Catalytic residues | |||
---|---|---|---|
Position | Amino acid | Present? | |
Domain | Protein | ||
N/A | N/A | E | No |
N/A | N/A | D | No |
N/A | N/A | K | No |
NDFIQKIASNTYACKHAEVQSILKMSHPQEPELMNAN
The domain was found using the schnipsel database
S_TKcSerine/Threonine protein kinases, catalytic domain |
---|
SMART accession number: | SM00220 |
---|---|
Description: | Phosphotransferases. Serine or threonine-specific kinase subfamily. |
Interpro abstract (IPR000719): | Protein phosphorylation, which plays a key role in most cellular activities, is a reversible process mediated by protein kinases and phosphoprotein phosphatases. Protein kinases catalyse the transfer of the gamma phosphate from nucleotide triphosphates (often ATP) to one or more amino acid residues in a protein substrate side chain, resulting in a conformational change affecting protein function. Phosphoprotein phosphatases catalyse the reverse process. Protein kinases fall into three broad classes, characterised with respect to substrate specificity [ (PUBMED:3291115) ]:
Protein kinase function is evolutionarily conserved from Escherichia coli to human [ (PUBMED:12471243) ]. Protein kinases play a role in a multitude of cellular processes, including division, proliferation, apoptosis, and differentiation [ (PUBMED:12368087) ]. Phosphorylation usually results in a functional change of the target protein by changing enzyme activity, cellular location, or association with other proteins. The catalytic subunits of protein kinases are highly conserved, and several structures have been solved [ (PUBMED:15078142) ], leading to large screens to develop kinase-specific inhibitors for the treatments of a number of diseases [ (PUBMED:15320712) ]. Eukaryotic protein kinases [ (PUBMED:12734000) (PUBMED:7768349) (PUBMED:1835513) (PUBMED:1956325) (PUBMED:3291115) ] are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common with both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. In the central part of the catalytic domain there is a conserved aspartic acid residue which is important for the catalytic activity of the enzyme [ (PUBMED:1862342) ]. This entry represents the protein kinase domain containing the catalytic function of protein kinases [ (PUBMED:1956325) ]. This domain is found in serine/threonine-protein kinases, tyrosine-protein kinases and dual specificity protein kinases. |
GO process: | protein phosphorylation (GO:0006468) |
GO function: | protein kinase activity (GO:0004672), ATP binding (GO:0005524) |
Family alignment: |
There are 221171 S_TKc domains in 218906 proteins in SMART's nrdb database.
Click on the following links for more information.
- Evolution (species in which this domain is found)
-
Taxonomic distribution of proteins containing S_TKc domain.
This tree includes only several representative species. The complete taxonomic breakdown of all proteins with S_TKc domain is also avaliable.
Click on the protein counts, or double click on taxonomic names to display all proteins containing S_TKc domain in the selected taxonomic class.
- Cellular role (predicted cellular role)
-
Binding / catalysis: serine-specific phosphotransferase, threonine-specific phosphotransferase
- Literature (relevant references for this domain)
-
Primary literature is listed below; Automatically-derived, secondary literature is also avaliable.
- Lewis TS, Shapiro PS, Ahn NG
- Signal transduction through MAP kinase cascades.
- Adv Cancer Res. 1998; 74: 49-139
- Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D
- Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity.
- J Biol Chem. 1996; 271: 26157-64
- Display abstract
The discovery of several hundred different protein kinases involved in highly diverse cellular signaling pathways is in stark contrast to the much smaller number of known modulators of cell signaling. Of these, the H series protein kinase inhibitors (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7), N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H8) N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89)) are frequently used to block signaling pathways in studies of cellular regulation. To elucidate inhibition mechanisms at atomic resolution and to enable structure-based drug design of potential therapeutic modulators of signaling pathways, we determined the crystal structures of corresponding complexes with the cAPK catalytic subunit. Complexes with H7 and H8 (2.2 A) and with H89 (2.3 A) define the binding mode of the isoquinoline-sulfonamide derivatives in the ATP-binding site while demonstrating effects of ligand-induced structural change. Specific interactions between the enzyme and the inhibitors include the isoquinoline ring nitrogen ligating to backbone amide of Val-123 and an inhibitor side chain amide bonding to the backbone carbonyl of Glu-170. The conservation of the ATP-binding site of protein kinases allows evaluation of factors governing general selectivity of these inhibitors among kinases. These results should assist efforts in the design of protein kinase inhibitors with specific properties.
- Hanks SK, Hunter T
- Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification.
- FASEB J. 1995; 9: 576-96
- Display abstract
The eukaryotic protein kinases make up a large superfamily of homologous proteins. They are related by virtue of their kinase domains (also known as catalytic domains), which consist of approximately 250-300 amino acid residues. The kinase domains that define this group of enzymes contain 12 conserved subdomains that fold into a common catalytic core structure, as revealed by the 3-dimensional structures of several protein-serine kinases. There are two main subdivisions within the superfamily: the protein-serine/threonine kinases and the protein-tyrosine kinases. A classification scheme can be founded on a kinase domain phylogeny, which reveals families of enzymes that have related substrate specificities and modes of regulation.
- Owen DJ, Noble ME, Garman EF, Papageorgiou AC, Johnson LN
- Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product.
- Structure. 1995; 3: 467-82
- Display abstract
BACKGROUND: Control of intracellular events by protein phosphorylation is promoted by specific protein kinases. All the known protein kinase possess a common structure that defines a catalytically competent entity termed the 'kinase catalytic core'. Within this common structural framework each kinase displays its own unique substrate specificity, and a regulatory mechanism that may be modulated by association with other proteins. Structural studies of phosphorylase kinase (Phk), the major substrate of which is glycogen phosphorylase, may be expected to shed light on its regulation. RESULTS: We report two crystal structures of the catalytic core (residues 1-298; Phk gamma trnc) of the gamma-subunit of rabbit muscle phosphorylase kinase: the binary complex with Mn2+/beta-gamma-imidoadenosine 5'-triphosphate (AMPPNP) to a resolution of 2.6 A and the binary complex with Mg2+/ADP to a resolution of 3.0 A. The structures were solved by molecular replacement using the cAMP-dependent protein kinase (cAPK) as a model. CONCLUSIONS: The overall structure of Phk gamma trnc is similar to that of the catalytic core of other protein kinases. It consists of two domians joined on one edge by a 'hinge', with the catalytic site located in the cleft between the domains. Phk gamma trnc is constitutively active, and lacks the need for an activatory phosphorylation event that is essential for many kinases. The structure exhibits an essentially 'closed' conformation of the domains which is similar to that of cAPK complexed with substrates. The phosphorylated residue that is located at the domain interface in many protein kinases and that is believed to stabilize an active conformation is substituted by a glutamate in Phk gamma trnc. The glutamate, in a similar manner to the phosphorylated residue in other protein kinases, interacts with an arginine adjacent to the catalytic aspartate but does not participate in interdomain contacts. The interactions between the enzyme and the nucleotide product of its activity, Mg2+/ADP, explain the inhibitory properties of the nucleotides that are observed in kinetic studies.
- Schulze-Gahmen U et al.
- Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
- Proteins. 1995; 22: 378-91
- Display abstract
Cyclin-dependent kinases (CDKs) are conserved regulators of the eukaryotic cell cycle with different isoforms controlling specific phases of the cell cycle. Mitogenic or growth inhibitory signals are mediated, respectively, by activation or inhibition of CDKs which phosphorylate proteins associated with the cell cycle. The central role of CDKs in cell cycle regulation makes them a potential new target for inhibitory molecules with anti-proliferative and/or anti-neoplastic effects. We describe the crystal structures of the complexes of CDK2 with a weakly specific CDK inhibitor, N6-(delta 2-isopentenyl)adenine, and a strongly specific inhibitor, olomoucine. Both inhibitors are adenine derivatives and bind in the adenine binding pocket of CDK2, but in an unexpected and different orientation from the adenine of the authentic ligand ATP. The N6-benzyl substituent in olomoucine binds outside the conserved binding pocket and is most likely responsible for its specificity. The structural information from the CDK2-olomoucine complex will be useful in directing the search for the next generation inhibitors with improved properties.
- Zhang J, Zhang F, Ebert D, Cobb MH, Goldsmith EJ
- Activity of the MAP kinase ERK2 is controlled by a flexible surface loop.
- Structure. 1995; 3: 299-307
- Display abstract
BACKGROUND: The mitogen-activated protein (MAP) kinase, ERK2, is a tightly regulated enzyme in the ubiquitous Ras-activated protein kinase cascade. ERK2 is activated by phosphorylation at two sites, Y185 and T183, that lie in the phosphorylation lip at the mouth of the catalytic site. To ascertain the role of these two residues in securing the low-activity conformation of the enzymes we have carried out crystallographic analyses and assays of phosphorylation-site mutants of ERK2. RESULTS: The crystal structures of four mutants, T183E (threonine at residue 183 is replaced by glutamate), Y185E, Y185F and the double mutant T183E/Y185E, were determined. When T183 is replaced by glutamate, few conformational changes are observed. By contrast, when Y185 is replaced by glutamate, 19 residues become disordered, including the entire phosphorylation lip and an adjacent loop. The conservative substitution of phenylalanine for Y185 also induces relatively large conformational changes. A binding site for phosphotyrosine in the active enzyme is putatively identified on the basis of the high-resolution refinement of the structure of wild-type ERK2. CONCLUSIONS: The remarkable disorder observed throughout the phosphorylation lip when Y185 is mutated shows that the stability of the phosphorylation lip is rather low. Therefore, only modest amounts of binding energy will be required to dislodge the lip for phosphorylation, and it is likely that these residues will be involved in conformational changes associated with both with binding to kinases and phosphatases and with activation. Furthermore, the low-activity structure is specifically dependent on Y185, whereas there is no such dependency on T183. Both residues, however, participate in forming the active enzyme, contributing to its tight control.
- Taylor SS, Radzio-Andzelm E
- Three protein kinase structures define a common motif.
- Structure. 1994; 2: 345-55
- Display abstract
Structural comparisons between cAMP-dependent protein kinase, cyclin-dependent kinase 2 and mitogen-activated protein kinase reveal which features are common to the protein kinase family and which are enzyme-specific.
- Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ
- Atomic structure of the MAP kinase ERK2 at 2.3 A resolution.
- Nature. 1994; 367: 704-11
- Display abstract
The structure of the MAP kinase ERK2, a ubiquitous protein kinase target for regulation by Ras and Raf, has been solved in its unphosphorylated low-activity conformation to a resolution of 2.3 A. The two domains of unphosphorylated ERK2 are farther apart than in the active conformation of cAMP-dependent protein kinase and the peptide-binding site is blocked by tyrosine 185, one of the two residues that are phosphorylated in the active enzyme. Activation of ERK2 is thus likely to involve both global and local conformational changes.
- Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R
- Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24).
- EMBO J. 1993; 12: 849-59
- Display abstract
The crystal structure of the porcine heart catalytic subunit of cAMP-dependent protein kinase in a ternary complex with the MgATP analogue MnAMP-PNP and a pseudosubstrate inhibitor peptide, PKI(5-24), has been solved at 2.0 A resolution from monoclinic crystals of the catalytic subunit isoform CA. The refinement is presently at an R factor of 0.194 and the active site of the molecule is well defined. The glycine-rich phosphate anchor of the nucleotide binding fold motif of the protein kinase is a beta ribbon acting as a flap with conformational flexibility over the triphosphate group. The glycines seem to be conserved to avoid steric clash with ATP. The known synergistic effects of substrate binding can be explained by hydrogen bonds present only in the ternary complex. Implications for the kinetic scheme of binding order are discussed. The structure is assumed to represent a phosphotransfer competent conformation. The invariant conserved residue Asp166 is proposed to be the catalytic base and Lys168 to stabilize the transition state. In some tyrosine kinases Lys168 is functionally replaced by an Arg displaced by two residues in the primary sequence, suggesting invariance in three-dimensional space. The structure supports an in-line transfer with a pentacoordinate transition state at the phosphorus with very few nuclear movements.
- DeBondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH
- Crystal structure of cyclin-dependent kinase 2.
- Nature. 1993; 363: 595-602
- Display abstract
Cyclin-dependent kinase 2 (CDK2) is a member of a highly conserved family of protein kinases that regulate the eukaryotic cell cycle. The crystal structures of the human CDK2 apoenzyme and its Mg2+ ATP complex have been determined to 2.4 A resolution. The structure is bi-lobate, like that of the cyclic AMP-dependent protein kinase, but contains a unique helix-loop segment that interferes with ATP and protein substrate binding and probably plays a key part in the regulation of all cyclin-dependent kinases.
- Zheng J et al.
- Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor.
- Biochemistry. 1993; 32: 2154-61
- Display abstract
The structure of a ternary complex of the catalytic subunit of cAMP-dependent protein kinase, MgATP, and a 20-residue inhibitor peptide was determined at a resolution of 2.7 A using the difference Fourier technique starting from the model of the binary complex (Knighton et al., 1991a). The model of the ternary complex was refined using both X-PLOR and TNT to an R factor of 0.212 and 0.224, respectively. The orientation of the nucleotide and the interactions of MgATP with numerous conserved residues at the active site of the enzyme are clearly defined. The unique protein kinase nucleotide binding site consists of a five-stranded antiparallel beta-sheet with the base buried in a hydrophobic site along beta-strands 1 and 2 and fixed by hydrogen bonds to the N6 amino and N7 nitrogens. The small lobe secures the nucleotide via a glycine-rich loop and by ion pairing with Lys72 and Glu91. While the small lobe fixes the nontransferable alpha- and beta-phosphates in this inhibitor complex, the gamma-phosphate is secured by two Mg2+ ions and interacts both directly and indirectly with several residues in the large lobe--Asp184, Asn171, Lys168. Asp166 is positioned to serve as a catalytic base. The structure is correlated with previous chemical evidence, and the features that distinguish this nucleotide binding motif from other nucleotide binding proteins are delineated.
- Knighton DR, Zheng JH, TenEyck LF, Xuong NH, Taylor SS, Sowadski JM
- Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
- Science. 1991; 253: 414-20
- Display abstract
The structure of a 20-amino acid peptide inhibitor bound to the catalytic subunit of cyclic AMP-dependent protein kinase, and its interactions with the enzyme, are described. The x-ray crystal structure of the complex is the basis of the analysis. The peptide inhibitor, derived from a naturally occurring heat-stable protein kinase inhibitor, contains an amphipathic helix that is followed by a turn and an extended conformation. The extended region occupies the cleft between the two lobes of the enzyme and contains a five-residue consensus recognition sequence common to all substrates and peptide inhibitors of the catalytic subunit. The helical portion of the peptide binds to a hydrophobic groove and conveys high affinity binding. Loops from both domains converge at the active site and contribute to a network of conserved residues at the sites of magnesium adenosine triphosphate binding and catalysis. Amino acids associated with peptide recognition, nonconserved, extend over a large surface area.
- Knighton DR et al.
- Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
- Science. 1991; 253: 407-14
- Display abstract
The crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase complexed with a 20-amino acid substrate analog inhibitor has been solved and partially refined at 2.7 A resolution to an R factor of 0.212. The magnesium adenosine triphosphate (MgATP) binding site was located by difference Fourier synthesis. The enzyme structure is bilobal with a deep cleft between the lobes. The cleft is filled by MgATP and a portion of the inhibitor peptide. The smaller lobe, consisting mostly of amino-terminal sequence, is associated with nucleotide binding, and its largely antiparallel beta sheet architecture constitutes an unusual nucleotide binding motif. The larger lobe is dominated by helical structure with a single beta sheet at the domain interface. This lobe is primarily involved in peptide binding and catalysis. Residues 40 through 280 constitute a conserved catalytic core that is shared by more than 100 protein kinases. Most of the invariant amino acids in this conserved catalytic core are clustered at the sites of nucleotide binding and catalysis.
- Weber IT, Steitz TA, Bubis J, Taylor SS
- Predicted structures of cAMP binding domains of type I and II regulatory subunits of cAMP-dependent protein kinase.
- Biochemistry. 1987; 26: 343-51
- Display abstract
The mammalian cAMP-dependent protein kinases have regulatory (R) subunits that show substantial homology in amino acid sequence with the catabolite gene activator protein (CAP), a cAMP-dependent gene regulatory protein from Escherichia coli. Each R subunit has two in-tandem cAMP binding domains, and the structure of each of these domains has been modeled by analogy with the crystal structure of CAP. Both the type I and II regulatory subunits have been considered, so that four cAMP binding domains have been modeled. The binding of cAMP in general is analogous in all the structures and has been correlated with previous results based on photolabeling and binding of cAMP analogues. The model predicts that the first cAMP binding domain correlates with the previously defined fast dissociation site, which preferentially binds N6-substituted analogues of cAMP. The second domain corresponds to the slow dissociation site, which has a preference for C8-substituted analogues. The model also is consistent with cAMP binding in the syn conformation in both sites. Finally, this model has targeted specific regions that are likely to be involved in interdomain contacts. This includes contacts between the two cAMP binding domains as well as contacts with the amino-terminal region of the R subunit and with the catalytic subunit.
- Disease (disease genes where sequence variants are found in this domain)
-
SwissProt sequences and OMIM curated human diseases associated with missense mutations within the S_TKc domain.
Protein Disease Fibroblast growth factor receptor 3 (P22607) (SMART) OMIM:134934: Achondroplasia
OMIM:100800: Hypochondroplasia
OMIM:146000: Thanatophoric dysplasia, types I and II
OMIM:187600: Crouzon syndrome with acanthosis nigricans ; Muencke syndrome
OMIM:602849:
OMIM:600593: Craniosynostosis, Adelaide typeSerine/threonine-protein kinase receptor R3 (P37023) (SMART) OMIM:601284: Hereditary hemorrhagic telangiectasia-2
OMIM:600376:Cyclin-dependent kinase 4 (P11802) (SMART) OMIM:123829: Melanoma Insulin receptor (P06213) (SMART) OMIM:147670: Leprechaunism
OMIM:246200: Rabson-Mendenhall syndrome
OMIM:262190: Diabetes mellitus, insulin-resistant, with acanthosis nigricansMast/stem cell growth factor receptor Kit (P10721) (SMART) OMIM:164920: Piebaldism ; Mast cell leukemia ; Mastocytosis with associated hematologic disorder ; Germ cell tumors
OMIM:273300:Tyrosine-protein kinase BTK (Q06187) (SMART) OMIM:300300: Agammaglobulinemia, type 1, X-linked ; ?XLA and isolated growth hormone deficiency
OMIM:307200:Serine/threonine-protein kinase STK11 (Q15831) (SMART) OMIM:602216: Peutz-Jeghers syndrome
OMIM:175200:Ribosomal protein S6 kinase alpha-3 (P51812) (SMART) OMIM:300075: Coffin-Lowry syndrome
OMIM:303600: Mental retardation, X-linked nonspecific, type 19High affinity nerve growth factor receptor (P04629) (SMART) OMIM:191315: Insensitivity to pain, congenital, with anhidrosis
OMIM:256800: Medullary thyroid carcinoma, familial
OMIM:155240:Protein kinase C gamma type (P05129) (SMART) OMIM:176980: PROTEIN KINASE C, GAMMA; PRKCG Phosphorylase b kinase gamma catalytic chain, liver/testis isoform (P15735) (SMART) OMIM:172471: Glycogenosis, hepatic, autosomal Retinal guanylyl cyclase 1 (Q02846) (SMART) OMIM:601777: Cone dystrophy, progressive
OMIM:600179: Leber congenital amaurosis, type I
OMIM:204000: Cone-rod dystrophy 6
OMIM:601777:TGF-beta receptor type-2 (P37173) (SMART) OMIM:190182: Colon cancer ; Colorectal cancer, hereditary nonpolyposis, type 6
OMIM:114500: Esophageal cancer
OMIM:133239:Tyrosine-protein kinase ZAP-70 (P43403) (SMART) OMIM:176947: Selective T-cell defect Angiopoietin-1 receptor (Q02763) (SMART) OMIM:600221: Venous malformations, multiple cutaneous and mucosal
OMIM:600195:Rhodopsin kinase (Q15835) (SMART) OMIM:180381: Oguchi disease-2
OMIM:258100:Hepatocyte growth factor receptor (P08581) (SMART) OMIM:164860: Renal cell carcinoma, papillary, familial and sporadic
OMIM:605074: Hepatocellular carcinoma, childhood type
OMIM:114550:Proto-oncogene tyrosine-protein kinase receptor Ret (P07949) (SMART) OMIM:164761: Multiple endocrine neoplasia IIA
OMIM:171400: Medullary thyroid carcinoma
OMIM:155240: Multiple endocrine neoplasia IIB
OMIM:162300: Hirschsprung disease
OMIM:142623:
OMIM:188550: Thyroid papillary carcinoma - Metabolism (metabolic pathways involving proteins which contain this domain)
-
Click the image to view the interactive version of the map in iPath% proteins involved KEGG pathway ID Description 7.46 map04010 MAPK signaling pathway 3.88 map04912 GnRH signaling pathway 3.73 map04012 ErbB signaling pathway 3.58 map04910 Insulin signaling pathway 3.55 map04914 Progesterone-mediated oocyte maturation 3.54 map04510 Focal adhesion 2.72 map04720 Long-term potentiation 2.65 map04620 Toll-like receptor signaling pathway 2.62 map04310 Wnt signaling pathway 2.62 map04540 Gap junction 2.57 map04664 Fc epsilon RI signaling pathway 2.56 map04370 VEGF signaling pathway 2.53 map04150 mTOR signaling pathway 2.40 map04916 Melanogenesis 2.23 map04810 Regulation of actin cytoskeleton 2.10 map05214 Glioma 2.06 map04020 Calcium signaling pathway 2.04 map05223 Non-small cell lung cancer 2.01 map00632 Benzoate degradation via CoA ligation 2.01 map00562 Inositol phosphate metabolism 2.00 map05211 Renal cell carcinoma 1.97 map04530 Tight junction 1.92 map04360 Axon guidance 1.70 map05215 Prostate cancer 1.67 map05221 Acute myeloid leukemia 1.55 map04110 Cell cycle 1.52 map05212 Pancreatic cancer 1.51 map05213 Endometrial cancer 1.51 map04650 Natural killer cell mediated cytotoxicity 1.48 map05210 Colorectal cancer 1.48 map04730 Long-term depression 1.46 map05120 Epithelial cell signaling in Helicobacter pylori infection 1.42 map04670 Leukocyte transendothelial migration 1.39 map04920 Adipocytokine signaling pathway 1.36 map05220 Chronic myeloid leukemia 1.35 map04660 T cell receptor signaling pathway 1.29 map05218 Melanoma 1.24 map04740 Olfactory transduction 1.18 map05219 Bladder cancer 1.02 map04210 Apoptosis 1.01 map04520 Adherens junction 1.01 map04350 TGF-beta signaling pathway 0.92 map04340 Hedgehog signaling pathway 0.87 map04115 p53 signaling pathway 0.81 map04111 Cell cycle - yeast 0.80 map05216 Thyroid cancer 0.77 map04930 Type II diabetes mellitus 0.70 map04320 Dorso-ventral axis formation 0.68 map05222 Small cell lung cancer 0.65 map04140 Regulation of autophagy 0.61 map04742 Taste transduction 0.59 map04662 B cell receptor signaling pathway 0.46 map04630 Jak-STAT signaling pathway 0.43 map04070 Phosphatidylinositol signaling system 0.31 map05217 Basal cell carcinoma 0.19 map03320 PPAR signaling pathway 0.18 map05010 Alzheimer's disease 0.09 map04120 Ubiquitin mediated proteolysis 0.03 map00540 Lipopolysaccharide biosynthesis This information is based on mapping of SMART genomic protein database to KEGG orthologous groups. Percentage points are related to the number of proteins with S_TKc domain which could be assigned to a KEGG orthologous group, and not all proteins containing S_TKc domain. Please note that proteins can be included in multiple pathways, ie. the numbers above will not always add up to 100%.
- Structure (3D structures containing this domain)
3D Structures of S_TKc domains in PDB
PDB code Main view Title 1a06 CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT 1a9u THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580 1apm 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT 1aq1 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE 1atp 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR 1b38 HUMAN CYCLIN-DEPENDENT KINASE 2 1b39 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 1bi7 MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX 1bi8 MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX 1bkx A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY 1bl6 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995 1bl7 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025 1blx P19INK4D/CDK6 COMPLEX 1bmk THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655 1buh CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1 1bx6 CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE 1cdk CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C 1ckp HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B 1cm8 PHOSPHORYLATED MAP KINASE P38-GAMMA 1cmk CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS 1ctp STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION 1daw CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP 1day CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP 1di8 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE 1di9 THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-6,7-DIMETHOXYQUINAZOLINE 1dm2 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE 1ds5 DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME. 1e1v HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 1e1x HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 1e9h Thr 160 phosphorylated CDK2 - Human cyclin A3 complex with the inhibitor indirubin-5-sulphonate bound 1erk STRUCTURE OF SIGNAL-REGULATED KINASE 1f0q CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN 1f3m CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1 1f5q CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2 1fin CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX 1fmo CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE 1fot STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE 1fq1 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2 1fvt THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR 1fvv THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR 1g3n STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX 1g5s CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717 1gih HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR 1gii HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR 1gij HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR 1gng Glycogen synthase kinase-3 beta (GSK3) complex with FRATtide peptide 1gol COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52 1gy3 pCDK2/cyclin A in complex with MgADP, nitrate and peptide substrate 1gz8 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-Amino-6-(3'-methyl-2'-oxo)butoxypurine 1gzk Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation 1gzn Structure of PKB kinase domain 1gzo Structure of protein kinase B unphosphorylated 1h00 CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor 1h01 CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor 1h07 CDK2 in complex with a disubstituted 4, 6-bis anilino pyrimidine CDK4 inhibitor 1h08 CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor 1h0v Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[(R)-pyrrolidino-5'-yl]methoxypurine 1h0w Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-Amino-6-[cyclohex-3-enyl]methoxypurine 1h1p Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU2058 1h1q Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094 1h1r Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6086 1h1s Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6102 1h1w High resolution crystal structure of the human PDK1 catalytic domain 1h24 CDK2/CyclinA in complex with a 9 residue recruitment peptide from E2F 1h25 CDK2/CyclinA in complex with an 11-residue recruitment peptide from E2F 1h26 CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 1h27 CDK2/CyclinA in complex with an 11-residue recruitment peptide from p27 1h28 CDK2/CyclinA in complex with an 11-residue recruitment peptide from p107 1h4l Structure and regulation of the CDK5-p25(nck5a) complex 1h8f Glycogen Synthase Kinase 3 beta. 1hck HUMAN CYCLIN-DEPENDENT KINASE 2 1hcl HUMAN CYCLIN-DEPENDENT KINASE 2 1how THE X-RAY CRYSTAL STRUCTURE OF SKY1P, AN SR PROTEIN KINASE IN YEAST 1i09 STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B) 1ia8 THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1 1ian HUMAN P38 MAP KINASE INHIBITOR COMPLEX 1ig1 1.8A X-Ray structure of ternary complex of a catalytic domain of death-associated protein kinase with ATP analogue and Mn. 1j1b Binary complex structure of human tau protein kinase I with AMPPNP 1j1c Binary complex structure of human tau protein kinase I with ADP 1j3h Crystal structure of apoenzyme cAMP-dependent protein kinase catalytic subunit 1j91 Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the ATP-competitive inhibitor 4,5,6,7-tetrabromobenzotriazole 1jam Crystal structure of apo-form of Z. Mays CK2 protein kinase alpha subunit 1jbp Crystal Structure of the Catalytic Subunit of cAMP-dependent Protein Kinase Complexed with a Substrate Peptide, ADP and Detergent 1jkk 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG. 1jkl 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE 1jks 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1jkt TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1jlu Crystal Structure of the Catalytic Subunit of cAMP-dependent Protein Kinase Complexed with a Phosphorylated Substrate Peptide and Detergent 1jnk THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP 1jow Crystal structure of a complex of human CDK6 and a viral cyclin 1jst PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A 1jsu P27(KIP1)/CYCLIN A/CDK2 COMPLEX 1jsv The structure of cyclin-dependent kinase 2 (CDK2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]benzenesulfonamide 1jvp Crystal structure of human CDK2 (unphosphorylated) in complex with PKF049-365 1jwh Crystal Structure of Human Protein Kinase CK2 Holoenzyme 1ke5 CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide 1ke6 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE 1ke7 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE 1ke8 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE 1ke9 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE 1koa TWITCHIN KINASE FRAGMENT (C.ELEGANS), AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS 1kob TWITCHIN KINASE FRAGMENT (APLYSIA), AUTOREGULATED PROTEIN KINASE DOMAIN 1kv1 p38 MAP Kinase in Complex with Inhibitor 1 1kv2 Human p38 MAP Kinase in Complex with BIRB 796 1kwp Crystal Structure of MAPKAP2 1l3r Crystal Structure of a Transition State Mimic of the Catalytic Subunit of cAMP-dependent Protein Kinase 1lew CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A 1lez CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B 1lp4 Crystal structure of a binary complex of the catalytic subunit of protein kinase CK2 with Mg-AMPPNP 1lpu Low Temperature Crystal Structure of the Apo-form of the catalytic subunit of protein kinase CK2 from Zea mays 1lr4 Room Temperature Crystal Structure of the Apo-form of the catalytic subunit of protein kinase CK2 from Zea mays 1m2p Crystal structure of 1,8-di-hydroxy-4-nitro-anthraquinone/CK2 kinase complex 1m2q Crystal structure of 1,8-di-hydroxy-4-nitro-xanten-9-one/CK2 kinase complex 1m2r Crystal structure of 5,8-di-amino-1,4-di-hydroxy-anthraquinone/CK2 kinase complex 1m7q Crystal structure of p38 MAP kinase in complex with a dihydroquinazolinone inhibitor 1mq4 Crystal Structure of Aurora-A Protein Kinase 1mru Intracellular Ser/Thr protein kinase domain of Mycobacterium tuberculosis PknB. 1mrv crystal structure of an inactive Akt2 kinase domain 1mry crystal structure of an inactive akt2 kinase domain 1muo CRYSTAL STRUCTURE OF AURORA-2, AN ONCOGENIC SERINE-THREONINE KINASE 1na7 Crystal structure of the catalytic subunit of human protein kinase CK2 1nvq The Complex Structure Of Checkpoint Kinase Chk1/UCN-01 1nvr The Complex Structure Of Checkpoint Kinase Chk1/Staurosporine 1nvs The Complex Structure Of Checkpoint Kinase Chk1/SB218078 1nxk Crystal structure of staurosporine bound to MAP KAP kinase 2 1ny3 Crystal structure of ADP bound to MAP KAP kinase 2 1o6k Structure of activated form of PKB kinase domain S474D with GSK3 peptide and AMP-PNP 1o6l Crystal structure of an activated Akt/protein kinase B (PKB-PIF chimera) ternary complex with AMP-PNP and GSK3 peptide 1o6y Catalytic domain of PknB kinase from Mycobacterium tuberculosis 1o9u GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE 1ob3 Structure of P. falciparum PfPK5 1ogu STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR 1oi9 Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor 1oiq Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation 1oir Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation 1oit Imidazopyridines: a potent and selective class of Cyclin-dependent Kinase inhibitors identified through Structure-based hybridisation 1oiu Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor 1oiy Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor 1okv Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2 1okw Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2 1oky Structure of human PDK1 kinase domain in complex with staurosporine 1okz Structure of human PDK1 kinase domain in complex with UCN-01 1ol1 Cyclin A binding groove inhibitor H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2 1ol2 Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2 1ol5 Structure of Aurora-A 122-403, phosphorylated on Thr287, Thr288 and bound to TPX2 1-43 1ol6 Structure of unphosphorylated D274N mutant of Aurora-A 1ol7 Structure of Human Aurora-A 122-403 phosphorylated on Thr287, Thr288 1om1 Crystal structure of maize CK2 alpha in complex with IQA 1omw Crystal Structure of the complex between G Protein-Coupled Receptor Kinase 2 and Heterotrimeric G Protein beta 1 and gamma 2 subunits 1ouk The structure of p38 alpha in complex with a pyridinylimidazole inhibitor 1ouy The structure of p38 alpha in complex with a dihydropyrido-pyrimidine inhibitor 1ove The structure of p38 alpha in complex with a dihydroquinolinone 1oz1 P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR 1p2a The structure of cyclin dependent kinase 2 (CKD2) with a trisubstituted naphthostyril inhibitor 1p38 THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION 1p4f DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT 1p5e The strucure of phospho-CDK2/cyclin A in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (TBS) 1pf8 Crystal Structure of Human Cyclin-Dependent Kinase 2 Complexed with a Nucleoside Inhibitor 1phk TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE, KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE, SUBSTRATE-ANALOGUE AND PRODUCT 1pjk Crystal Structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit 1pkd THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A 1pme STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE 1pmn Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitor 1pmu The crystal structure of JNK3 in complex with a phenantroline inhibitor 1pmv The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitor 1pw2 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 1pxi HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,5-Dichloro-thiophen-3-yl)-pyrimidin-2-ylamine 1pxj HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine 1pxk HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)pyrimidin-2-yl]-N'-hydroxyiminoformamide 1pxl HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine 1pxm HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol 1pxn HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-Methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol 1pxo HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine 1pxp HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-N',N'-dimethyl-benzene-1,4-diamine 1pye Crystal structure of CDK2 with inhibitor 1pyx GSK-3 Beta complexed with AMP-PNP 1q24 PKA double mutant model of PKB in complex with MgATP 1q3d GSK-3 Beta complexed with Staurosporine 1q3w GSK-3 Beta complexed with Alsterpaullone 1q41 GSK-3 Beta complexed with Indirubin-3'-monoxime 1q4l GSK-3 Beta complexed with Inhibitor I-5 1q5k crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor 1q61 PKA triple mutant model of PKB 1q62 PKA double mutant model of PKB 1q8t The Catalytic Subunit of cAMP-dependent Protein Kinase (PKA) in Complex with Rho-kinase Inhibitor Y-27632 1q8u The Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Rho-kinase Inhibitor H-1152P 1q8w The Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Rho-kinase Inhibitor Fasudil (HA-1077) 1q8y The structure of the yeast SR protein kinase, Sky1p, with bound ADP 1q8z The apoenzyme structure of the yeast SR protein kinase, Sky1p 1q97 The structure of the Saccharomyces cerevisiae SR protein kinase, Sky1p, with bound ATP 1q99 Crystal structure of the Saccharomyces cerevisiae SR protein kinsae, Sky1p, complexed with the non-hydrolyzable ATP analogue, AMP-PNP 1ql6 THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES 1qmz PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX 1r0e Glycogen synthase kinase-3 beta in complex with 3-indolyl-4-arylmaleimide inhibitor 1r39 THE STRUCTURE OF P38ALPHA 1r3c THE STRUCTURE OF P38ALPHA C162S MUTANT 1r78 CDK2 complex with a 4-alkynyl oxindole inhibitor 1rdq Hydrolysis of ATP in the crystal of Y204A mutant of cAMP-dependent protein kinase 1re8 Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 2 1rej Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 1 1rek Crystal structure of cAMP-dependent protein kinase complexed with balanol analog 8 1s9i X-ray structure of the human mitogen-activated protein kinase kinase 2 (MEK2)in a complex with ligand and MgATP 1s9j X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP 1smh Protein kinase A variant complex with completely ordered N-terminal helix 1stc CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE 1sve Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 1 1svg Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 4 1svh Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 8 1syk Crystal structure of E230Q mutant of cAMP-dependent protein kinase reveals unexpected apoenzyme conformation 1szm DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA) 1tki AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN 1tvo The structure of ERK2 in complex with a small molecule inhibitor 1u5q Crystal Structure of the TAO2 Kinase Domain: Activation and Specifity of a Ste20p MAP3K 1u5r Crystal Structure of the TAO2 Kinase Domain: Activation and Specifity of a Ste20p MAP3K 1ua2 Crystal Structure of Human CDK7 1ukh Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 1uki Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 1ung Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin. 1unh Structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine and indirubin. 1unl Structural mechanism for the inhibition of CD5-p25 from the roscovitine, aloisine and indirubin. 1urc Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly 1urw CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-b]PYRIDAZINE 1uu3 Structure of human PDK1 kinase domain in complex with LY333531 1uu7 Structure of human PDK1 kinase domain in complex with BIM-2 1uu8 Structure of human PDK1 kinase domain in complex with BIM-1 1uu9 Structure of human PDK1 kinase domain in complex with BIM-3 1uv5 GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3'-OXIME 1uvr Structure of human PDK1 kinase domain in complex with BIM-8 1v0b Crystal structure of the t198a mutant of pfpk5 1v0o Structure of P. falciparum PfPK5-Indirubin-5-sulphonate ligand complex 1v0p Structure of P. falciparum PfPK5-Purvalanol B ligand complex 1v1k CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR 1veb Crystal Structure of Protein Kinase A in Complex with Azepane Derivative 5 1vyw Structure of CDK2/Cyclin A with PNU-292137 1vyz Structure of CDK2 complexed with PNU-181227 1vzo The structure of the N-terminal kinase domain of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein 1w0x Crystal structure of human CDK2 in complex with the inhibitor olomoucine. 1w7h p38 Kinase crystal structure in complex with small molecule inhibitor 1w82 p38 Kinase crystal structure in complex with small molecule inhibitor 1w83 p38 Kinase crystal structure in complex with small molecule inhibitor 1w84 p38 Kinase crystal structure in complex with small molecule inhibitor 1w8c CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H-PURIN-2- YLAMINE AND MONOMERIC CDK2 1w98 The structural basis of CDK2 activation by cyclin E 1wbn fragment based p38 inhibitors 1wbo fragment based p38 inhibitors 1wbs Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation. 1wbt Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation. 1wbv Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation. 1wbw Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead generation. 1wcc screening for fragment binding by X-ray crystallography 1wfc STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN 1wmk Human death-associated kinase DRP-1, mutant S308D d40 1wvw Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors 1wvx Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors 1wvy Crystal structures of kinase domain of DAP kinase in complex with small molecular inhibitors 1wzy Crystal structure of human ERK2 complexed with a pyrazolopyridazine derivative 1xh4 Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants 1xh5 Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants 1xh6 Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants 1xh7 Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants 1xh8 Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants 1xh9 Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants 1xha Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants 1xjd Crystal Structure of PKC-theta complexed with Staurosporine at 2A resolution 1xo2 Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin 1xqz Crystal Structure of hPim-1 kinase at 2.1 A resolution 1xr1 Crystal structure of hPim-1 kinase in complex with AMP-PNP at 2.1 A Resolution 1xws Crystal Structure of the human PIM1 kinase domain 1y8g Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Inactive double mutant with selenomethionine 1y8y Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor 1y91 Crystal structure of human CDK2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor 1ydr STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE 1yds STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE 1ydt STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE 1yhs Crystal structure of Pim-1 bound to staurosporine 1yhv Crystal Structure of PAK1 kinase domain with two point mutations (K299R, T423E) 1yhw Crystal Structure of PAK1 kinase domain with one point mutations (K299R) 1yi3 Crystal Structure of Pim-1 bound to LY294002 1yi4 Structure of Pim-1 bound to adenosine 1ykr Crystal structure of cdk2 with an aminoimidazo pyridine inhibitor 1ym7 G Protein-Coupled Receptor Kinase 2 (GRK2) 1yqj Crystal Structure of p38 Alpha in Complex with a Selective Pyridazine Inhibitor 1yrp Catalytic domain of human ZIP kinase phosphorylated at Thr265 1yw2 Mutated Mus Musculus P38 Kinase (mP38) 1ywr Crystal Structure Analysis of inactive P38 kinase domain in complex with a Monocyclic Pyrazolone Inhibitor 1ywv Crystal Structures of Proto-Oncogene Kinase Pim1: a Target of Aberrant Somatic Hypermutations in Diffuse Large Cell Lymphoma 1yxs Crystal Structure of Kinase Pim1 with P123M mutation 1yxt Crystal Structure of Kinase Pim1 in complex with AMPPNP 1yxu Crystal Structure of Kinase Pim1 in Complex with AMP 1yxv Crystal Structure of Kinase Pim1 in complex with 3,4-Dihydroxy-1-methylquinolin-2(1H)-one 1yxx Crystal Structure of Kinase Pim1 in complex with (3E)-3-[(4-HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE 1z57 Crystal structure of human CLK1 in complex with 10Z-Hymenialdisine 1z5m Crystal Structure Of N1-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethylpropanediamide Complexed with Human PDK1 1z9x Human DRP-1 kinase, W305S S308A D40 mutant, crystal form with 3 monomers in the asymmetric unit 1zlt Crystal Structure of Chk1 Complexed with a Hymenaldisine Analog 1zmu Catalytic and ubiqutin-associated domains of MARK2/PAR-1: Wild type 1zmv Catalytic and ubiqutin-associated domains of MARK2/PAR-1: K82R mutant 1zmw Catalytic and ubiqutin-associated domains of MARK2/PAR-1: T208A/S212A inactive double mutant 1zoe Crystal structure of protein kinase CK2 in complex with TBB-derivatives inhibitors 1zog Crystal structure of protein kinase CK2 in complex with TBB-derivatives 1zoh Crystal structure of protein kinase CK2 in complex with TBB-derivatives inhibitors 1zrz Crystal Structure of the Catalytic Domain of Atypical Protein Kinase C-iota 1zws Crystal structure of the catalytic domain of human DRP-1 kinase 1zxe Crystal Structure of eIF2alpha Protein Kinase GCN2: D835N Inactivating Mutant in Apo Form 1zy4 Crystal Structure of eIF2alpha Protein Kinase GCN2: R794G Hyperactivating Mutant in Apo Form. 1zy5 Crystal Structure of eIF2alpha Protein Kinase GCN2: R794G Hyperactivating Mutant Complexed with AMPPNP. 1zyc Crystal Structure of eIF2alpha Protein Kinase GCN2: Wild-Type in Apo Form. 1zyd Crystal Structure of eIF2alpha Protein Kinase GCN2: Wild-Type Complexed with ATP. 1zyj Human P38 MAP Kinase in Complex with Inhibitor 1a 1zys Co-crystal structure of Checkpoint Kinase Chk1 with a pyrrolo-pyridine inhibitor 1zz2 Two Classes of p38alpha MAP Kinase Inhibitors Having a Common Diphenylether Core but Exhibiting Divergent Binding Modes 1zzl Crystal structure of P38 with triazolopyridine 2a0c Human CDK2 in complex with olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor 2a27 Human DRP-1 kinase, W305S S308A D40 mutant, crystal form with 8 monomers in the asymmetric unit 2a2a High-resolution crystallographic analysis of the autoinhibited conformation of a human death-associated protein kinase 2a4l Human cyclin-dependent kinase 2 in complex with roscovitine 2ac3 Structure of human Mnk2 Kinase Domain 2ac5 Structure of human Mnk2 Kinase Domain mutant D228G 2acx Crystal Structure of G protein coupled receptor kinase 6 bound to AMPPNP 2ayp Crystal Structure of CHK1 with an Indol Inhibitor 2b1p inhibitor complex of JNK3 2b52 Human cyclin dependent kinase 2 (CDK2) complexed with DPH-042562 2b53 Human cyclin dependent kinase 2 (CDK2) complexed with DIN-234325 2b54 Human cyclin dependent kinase 2 (CKD2)complexed with DIN-232305 2b55 Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole DIN-101312 2b9f Crystal structure of non-phosphorylated Fus3 2b9h Crystal structure of Fus3 with a docking motif from Ste7 2b9i Crystal structure of Fus3 with a docking motif from Msg5 2b9j Crystal structure of Fus3 with a docking motif from Far1 2baj p38alpha bound to pyrazolourea 2bak p38alpha MAP kinase bound to MPAQ 2bal p38alpha MAP kinase bound to pyrazoloamine 2baq p38alpha bound to Ro3201195 2bcj Crystal Structure of G Protein-Coupled Receptor Kinase 2 in Complex with Galpha-q and Gbetagamma Subunits 2bdw Crystal Structure of the Auto-Inhibited Kinase Domain of Calcium/Calmodulin Activated Kinase II 2bfx Mechanism of Aurora-B activation by INCENP and inhibition by Hesperadin. 2bfy complex of Aurora-B with INCENP and Hesperidin. 2bhe HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE 2bhh HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE 2bik Human Pim1 phosphorylated on Ser261 2bil The human protein kinase Pim1 in complex with its consensus peptide Pimtide 2biy Structure of PDK1-S241A mutant kinase domain 2bkz STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 2bmc Aurora-2 T287D T288D complexed with PNU-680632 2bpm STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 2br1 Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity 2brb Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity 2brg Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity 2brh Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity 2brm Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity 2brn Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity 2bro Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand Affinity 2btr STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 2bts STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 2bva Crystal structure of the human P21-activated kinase 4 2bzh CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1 2bzi CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2 2bzj CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3 2bzk CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE 2c1a Structure of cAMP-dependent protein kinase complexed with Isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino) ethyl)amide 2c1b Structure of cAMP-dependent protein kinase complexed with (4R,2S)-5'-( 4-(4-Chlorobenzyloxy)pyrrolidin-2-ylmethanesulfonyl)isoquinoline 2c30 Crystal Structure Of The Human P21-Activated Kinase 6 2c3i CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I 2c3j Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification 2c3k Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification 2c3l Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification 2c4g STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 2c5n Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design 2c5o Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design 2c5v Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design 2c5x Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design 2c5y DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN 2c68 Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2c69 Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2c6d Aurora A kinase activated mutant (T287D) in complex with ADPNP 2c6e Aurora A kinase activated mutant (T287D) in complex with a 5- aminopyrimidinyl quinazoline inhibitor 2c6i Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2c6k Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2c6l Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2c6m Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2c6o Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2c6t Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor 2cch The crystal structure of CDK2 cyclin A in complex with a substrate peptide derived from CDC modified with a gamma-linked ATP analogue 2cci Crystal structure of phospho-CDK2 Cyclin A in complex with a peptide containing both the substrate and recruitment sites of CDC6 2cdz CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A 2cgu Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening 2cgv Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening 2cgw Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening 2cgx Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening 2cjm Mechanism of CDK inhibition by active site phosphorylation: CDK2 Y15p T160p in complex with cyclin A structure 2cke Human death-associated DRP-1 kinase in complex with inhibitor 2clq Structure of mitogen-activated protein kinase kinase kinase 5 2clx 4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects 2cn5 Crystal structure of human Chk2 in complex with ADP 2cn8 Crystal structure of human Chk2 in complex with debromohymenialdisine 2cpk CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE 2ds1 Human cyclin dependent kinase 2 complexed with the CDK4 inhibitor 2duv Structure of CDK2 with a 3-hydroxychromones 2dwb Aurora-A kinase complexed with AMPPNP 2dyl Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (S287D, T291D) 2e9n Structure of h-CHK1 complexed with A767085 2e9o Structure of h-CHK1 complexed with AA582939 2e9p Structure of h-CHK1 complexed with A771129 2e9u Structure of h-CHK1 complexed with A780125 2e9v Structure of h-CHK1 complexed with A859017 2erk PHOSPHORYLATED MAP KINASE ERK2 2erz Crystal Structure of c-AMP Dependent Kinase (PKA) bound to hydroxyfasudil 2esm Crystal Structure of ROCK 1 bound to fasudil 2etk Crystal Structure of ROCK 1 bound to hydroxyfasudil 2etr Crystal Structure of ROCK I bound to Y-27632 2eu9 Crystal Structure of CLK3 2euf X-ray structure of human CDK6-Vcyclin in complex with the inhibitor PD0332991 2ewa Dual binding mode of pyridinylimidazole to MAP kinase p38 2exc Inhibitor complex of JNK3 2exe Crystal structure of the phosphorylated CLK3 2exm Human CDK2 in complex with isopentenyladenine 2f2c X-ray structure of human CDK6-Vcyclinwith the inhibitor aminopurvalanol 2f2u crystal structure of the Rho-kinase kinase domain 2f49 Crystal structure of Fus3 in complex with a Ste5 peptide 2f57 Crystal Structure Of The Human P21-Activated Kinase 5 2f7e PKA complexed with (S)-2-(1H-Indol-3-yl)-1-(5-isoquinolin-6-yl-pyridin-3-yloxymethyl-etylamine 2f7x Protein Kinase A bound to (S)-2-(1H-Indol-3-yl)-1-[5-((E)-2-pyridin-4-yl-vinyl)-pyridin-3-yloxymethyl]-ethylamine 2f7z Protein Kinase A bound to (R)-1-(1H-Indol-3-ylmethyl)-2-(2-pyridin-4-yl-[1,7]naphtyridin-5-yloxy)-ehylamine 2f9g Crystal structure of Fus3 phosphorylated on Tyr182 2fa2 Crystal structure of Fus3 without a peptide from Ste5 2fh9 Structure and dimerization of the kinase domain from yeast Snf1 2fsl mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-A 2fsm mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-B 2fso mitogen activated protein kinase p38alpha (D176A) activating mutant 2fst mitogen activated protein kinase p38alpha (D176A+F327L) activating mutant 2fum Catalytic domain of protein kinase PknB from Mycobacterium tuberculosis in complex with mitoxantrone 2fvd Cyclin Dependent Kinase 2 (CDK2) with diaminopyrimidine inhibitor 2fys Crystal structure of Erk2 complex with KIM peptide derived from MKP3 2g01 Pyrazoloquinolones as Novel, Selective JNK1 inhibitors 2g9x Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271 2gcd TAO2 kinase domain-staurosporine structure 2gdo 4-(Aminoalkylamino)-3-Benzimidazole-Quinolinones As Potent CHK1 Inhibitors 2gfc cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24 2gfs P38 Kinase Crystal Structure in complex with RO3201195 2ghg h-CHK1 complexed with A431994 2ghl Mutant Mus Musculus P38 Kinase Domain in Complex with Inhibitor PG-874743 2ghm Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-895449 2gmx Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity 2gnf Protein kinase A fivefold mutant model of Rho-kinase with Y-27632 2gng Protein kinase A fivefold mutant model of Rho-kinase 2gnh PKA five fold mutant model of Rho-kinase with H1152P 2gni PKA fivefold mutant model of Rho-kinase with inhibitor Fasudil (HA1077) 2gnj PKA three fold mutant model of Rho-kinase with Y-27632 2gnl PKA threefold mutant model of Rho-kinase with inhibitor H-1152P 2gph Docking motif interactions in the MAP kinase ERK2 2gtm Mutated Mouse P38 MAP Kinase Domain in complex with Inhibitor PG-892579 2gtn Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-951717 2gu8 Discovery of 2-Pyrimidyl-5-Amidothiophenes as Novel and Potent Inhibitors for AKT: Synthesis and SAR Studies 2h6d Protein Kinase Domain of the Human 5'-AMP-activated protein kinase catalytic subunit alpha-2 (AMPK alpha-2 chain) 2h96 Discovery of Potent, Highly Selective, and Orally Bioavailable Pyridine Carboxamide C-jun NH2-terminal Kinase Inhibitors 2h9v Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y27632 2hak Catalytic and ubiqutin-associated domains of MARK1/PAR-1 2hog crystal structure of Chek1 in complex with inhibitor 20 2hw6 Crystal structure of Mnk1 catalytic domain 2hw7 Crystal Structure of Mnk2-D228G in complex with Staurosporine 2hxl crystal structure of Chek1 in complex with inhibitor 1 2hxq crystal structure of Chek1 in complex with inhibitor 2 2hy0 crystal structure of chek1 in complex with inhibitor 22 2hy8 PAK1 complex with ST2001 2i0e Structure of catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor 2i0h The structure of p38alpha in complex with an arylpyridazinone 2i40 Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor 2i6l Crystal structure of human mitogen activated protein kinase 6 (MAPK6) 2iw6 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR 2iw8 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR 2iw9 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR 2iwi CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1 2j0i CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 2j2i Crystal Structure of the humab PIM1 in complex with LY333531 2j4z Structure of Aurora-2 in complex with PHA-680626 2j50 Structure of Aurora-2 in complex with PHA-739358 2j51 Crystal structure of Human STE20-like kinase bound to 5-Amino-3-((4-( aminosulfonyl)phenyl)amino) -N-(2,6-difluorophenyl)-1H-1,2,4-triazole- 1-carbothioamide 2j7t Crystal structure of human serine threonine kinase-10 bound to SU11274 2j90 Crystal structure of human ZIP kinase in complex with a tetracyclic pyridone inhibitor (Pyridone 6) 2j9m Crystal Structure of CDK2 in complex with Macrocyclic Aminopyrimidine 2jam Crystal structure of human calmodulin-dependent protein kinase I G 2jav Human Kinase with pyrrole-indolinone ligand 2jbo Protein kinase MK2 in complex with an inhibitor (crystal form-1, soaking) 2jbp Protein kinase MK2 in complex with an inhibitor (crystal form-2, co- crystallization) 2jc6 Crystal structure of human calmodulin-dependent protein kinase 1D 2jd5 Sky1p bound to Npl3p-derived substrate peptide 2jdo STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE 2jdr STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A-443654 2jds Structure of cAMP-dependent protein kinase complexed with A-443654 2jdt Structure of PKA-PKB chimera complexed with ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE 2jdv Structure of PKA-PKB chimera complexed with A-443654 2jed The crystal structure of the kinase domain of the protein kinase C theta in complex with NVP-XAA228 at 2.32A resolution. 2jfl CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(2,6- DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE 2jfm CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM) 2jgz Crystal structure of phospho-CDK2 in complex with Cyclin B 2jld Extremely Tight Binding of Ruthenium Complex to Glycogen Synthase Kinase 3 2lgc Joint NMR and X-ray refinement reveals the structure of a novel dibenzo[a,d]cycloheptenone inhibitor/p38 MAP kinase complex in solution 2no3 Novel 4-anilinopyrimidines as potent JNK1 Inhibitors 2np8 Structural Basis for the Inhibition of Aurora A Kinase by a Novel Class of High Affinity Disubstituted Pyrimidine Inhibitors 2npq A Novel Lipid Binding Site in the p38 alpha MAP Kinase 2o0u Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}-1-naphthalenecarboxamide 2o2u Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide 2o3p Crystal structure of Pim1 with Quercetin 2o5k Crystal Structure of GSK3beta in complex with a benzoimidazol inhibitor 2o63 Crystal structure of Pim1 with Myricetin 2o64 Crystal structure of Pim1 with Quercetagetin 2o65 Crystal structure of Pim1 with Pentahydroxyflavone 2obj Crystal structure of human PIM-1 Kinase in complex with inhibitor 2oh0 Crystal structure of Protein Kinase A in complex with Pyridine-Pyrazolopyridine Based Inhibitors 2oi4 Crystal structure of human PIM1 in complex with fluorinated ruthenium pyridocarbazole 2ojf Crystal structure of Protein Kinase A in complex with Pyridine-Pyrazolopyridine based inhibitors 2ojg Crystal structure of ERK2 in complex with N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide 2oji Crystal structure of ERK2 in complex with N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide 2ojj Crystal structure of ERK2 in complex with (S)-N-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide 2ok1 Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide 2okr Crystal Structure of the P38a-MAPKAP kinase 2 Heterodimer 2onl Crystal Structure of the p38a-MAPKAP kinase 2 Heterodimer 2ou7 Structure of the Catalytic Domain of Human Polo-like Kinase 1 2ow3 Glycogen synthase kinase-3 beta in complex with bis-(indole)maleimide pyridinophane inhibitor 2owb Structure of the Catalytic Domain of Human Polo-like Kinase 1 2oxd Protein kinase CK2 in complex with tetrabromobenzoimidazole K17, K22 and K32 inhibitors 2oxx Protein kinase CK2 in complex with tetrabromobenzoimidazole derivatives K17, K22 and K32 2oxy Protein kinase CK2 in complex with tetrabromobenzoimidazole derivatives K17, K22 and K32 2oza Structure of p38alpha complex 2p33 Synthesis and SAR of Aminopyrimidines as Novel c-Jun N-Terminal Kinase (JNK) Inhibitors 2p3g Crystal structure of a pyrrolopyridine inhibitor bound to MAPKAP Kinase-2 2p55 X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP 2pe0 CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-Hydroxy-3-[1-(1H-pyrrol-2-yl)-eth-(Z)-ylidene]-1,3-dihydro-indol-2-one COMPLEX 2pe1 CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-Oxo-3-[1-(1H-pyrrol-2-yl)-eth-(Z)-ylidene]-2,3-dihydro-1H-indol-5-yl}-urea {BX-517} COMPLEX 2pe2 CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-Oxo-5-ureido-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrol-3-yl}-N-(2-piperidin-1-yl-ethyl)-benzamide COMPLEX 2phk THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION 2pk9 Structure of the Pho85-Pho80 CDK-cyclin Complex of the Phosphate-responsive Signal Transduction Pathway 2pmi Structure of the Pho85-Pho80 CDK-cyclin Complex of the Phosphate-responsive Signal Transduction Pathway with Bound ATP-gamma-S 2puu Crystal structure of p38 complex with 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1-yl]urea 2pvh Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2 2pvj Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2 2pvk Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2 2pvl Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2 2pvm Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2 2pvn Structure-Based Design of Pyrazolo[1,5-a][1,3,5]triazine Derivatives as Potent Inhibitors of Protein Kinase CK2 2pvr Crystal structure of the catalytic subunit of protein kinase CK2 (C-terminal deletion mutant 1-335) in complex with two sulfate ions 2pzy Structure of MK2 Complexed with Compound 76 2q0n Structure of human p21 activating kinase 4 (PAK4) in complex with a consensus peptide 2qc6 Protein kinase CK2 in complex with DBC 2qcs A complex structure between the Catalytic and Regulatory subunit of Protein Kinase A that represents the inhibited state 2qd9 P38 Alpha Map Kinase inhibitor based on heterobicyclic scaffolds 2qg5 Cryptosporidium parvum calcium dependent protein kinase cgd7_1840 2qhm crystal structure of Chek1 in complex with inhibitor 2a 2qhn Crystal Structure of Chek1 in Complex with Inhibitor 1a 2qkr Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with indirubin 3'-monoxime bound 2qnj Kinase and Ubiquitin-associated domains of MARK3/Par-1 2qr7 2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2: Se-Met derivative 2qr8 2.0A X-ray structure of C-terminal kinase domain of p90 ribosomal S6 kinase 2 (RSK2) 2qur Crystal Structure of F327A/K285P Mutant of cAMP-dependent Protein Kinase 2qvs Crystal Structure of Type IIa Holoenzyme of cAMP-dependent Protein Kinase 2r0i Crystal structure of a kinase MARK2/Par-1 mutant 2r0u Crystal Structure of Chek1 in Complex with Inhibitor 54 2r3f Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3g Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3h Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3i Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3j Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3k Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3l Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3m Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3n Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3o Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3p Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3q Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r3r Crystal Structure of Cyclin-Dependent Kinase 2 with inhibitor 2r5t Crystal Structure of Inactive Serum and Glucocorticoid- Regulated Kinase 1 in Complex with AMP-PNP 2r64 Crystal structure of a 3-aminoindazole compound with CDK2 2r7b Crystal Structure of the Phosphoinositide-dependent Kinase-1 (PDK-1)Catalytic Domain bound to a dibenzonaphthyridine inhibitor 2r7i Crystal structure of catalytic subunit of protein kinase CK2 2r9s c-Jun N-terminal Kinase 3 with 3,5-Disubstituted Quinoline inhibitor 2rg5 Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11B 2rg6 Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11J 2rku Structure of PLK1 in complex with BI2536 2uue REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors 2uv2 Crystal Structure Of Human Ste20-Like Kinase Bound To 4-(4-(5- Cyclopropyl-1H-pyrazol-3-ylamino)-quinazolin-2-ylamino)-phenyl)- acetonitrile 2uvx Structure of PKA-PKB chimera complexed with 7-azaindole 2uvy Structure of PKA-PKB chimera complexed with methyl-(4-(9H-purin-6-yl)- benzyl)-amine 2uvz Structure of PKA-PKB chimera complexed with C-Phenyl-C-(4-(9H-purin-6- yl)-phenyl)-methylamine 2uw0 Structure of PKA-PKB chimera complexed with 6-(4-(4-(4-Chloro-phenyl) -piperidin-4-yl)-phenyl)-9H-purine 2uw3 Structure of PKA-PKB chimera complexed with 5-methyl-4-phenyl-1H- pyrazole 2uw4 Structure of PKA-PKB chimera complexed with 2-(4-(5-methyl-1H-pyrazol- 4-yl)-phenyl)-ethylamine 2uw5 Structure of PKA-PKB chimera complexed with (R)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine 2uw6 Structure of PKA-PKB chimera complexed with (S)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine 2uw7 Structure of PKA-PKB chimera complexed with 4-(4-chloro-phenyl)-4-(4- (1H-pyrazol-4-yl)-phenyl)-piperidine 2uw8 Structure of PKA-PKB chimera complexed with 2-(4-chloro-phenyl)-2- phenyl-ethylamine 2uw9 STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-chloro-phenyl)-4-(4-( 1H-pyrazol-4-yl)-phenyl)-piperidine 2uzb Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor 2uzd Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor 2uze Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor 2uzl Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor 2uzn Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor 2uzo Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor 2uzt PKA structures of AKT, indazole-pyridine inhibitors 2uzu PKA structures of indazole-pyridine series of AKT inhibitors 2uzv PKA structures of indazole-pyridine series of AKT inhibitors 2uzw PKA structures of indazole-pyridine series of AKT inhibitors 2v0d Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor 2v22 REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors 2v55 Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure 2v5q CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN 2v7o Crystal structure of human calcium-calmodulin-dependent protein kinase II gamma 2vag Crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor 2vd5 Structure of Human Myotonic Dystrophy Protein Kinase in Complex with the Bisindoylmaleide inhibitor BIM VIII 2vgo Crystal structure of Aurora B kinase in complex with Reversine inhibitor 2vgp Crystal structure of Aurora B kinase in complex with a aminothiazole inhibitor 2vn9 Crystal Structure of Human Calcium Calmodulin dependent Protein Kinase II delta isoform 1, CAMKD 2vnw Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)methanamine 2vny Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)amine 2vo0 Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorophenyl)-1-( 7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine 2vo3 Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorobenzyl)-1-( 7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine 2vo6 Structure of PKA-PKB chimera complexed with 4-(4-Chlorobenzyl)-1-(7H- pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-ylamine 2vo7 Structure of PKA complexed with 4-(4-Chlorobenzyl)-1-(7H-pyrrolo(2,3- d)pyrimidin-4-yl)piperidin-4-ylamine 2vrx Structure of Aurora B kinase in complex with ZM447439 2vta Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vth Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vti Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtj Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtl Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtm Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtn Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vto Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtp Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtq Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtr Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vts Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vtt Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vu3 Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. 2vv9 CDK2 in complex with an imidazole piperazine 2vwi Structure of the OSR1 kinase, a hypertension drug target 2vx3 Crystal structure of the human dual specificity tyrosine- phosphorylation-regulated kinase 1A 2vz6 Structure of human calcium calmodulin dependent protein kinase type II alpha (CAMK2A) in complex with Indirubin E804 2w05 Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5b 2w06 Structure of CDK2 in complex with an imidazolyl pyrimidine, compound 5c 2w0j Crystal structure of Chk2 in complex with NSC 109555, a specific inhibitor 2w17 CDK2 in complex with the imidazole pyrimidine amide, compound (S)-8b 2w1c Structure determination of Aurora Kinase in complex with inhibitor 2w1d Structure determination of Aurora Kinase in complex with inhibitor 2w1e Structure determination of Aurora Kinase in complex with inhibitor 2w1f Structure determination of Aurora Kinase in complex with inhibitor 2w1g Structure determination of Aurora Kinase in complex with inhibitor 2w1h Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi- targeted Kinase Inhibitor with Potent Aurora Kinase Activity 2w4j X-ray structure of a DAP-Kinase 2-277 2w4k X-ray structure of a DAP-Kinase 2-302 2w4o Crystal structure of Human CAMK4 in complex with 4-Amino(sulfamoyl- phenylamino)-triazole-carbothioic acid (2,6-difluoro-phenyl)-amide) 2w5a Human Nek2 kinase ADP-bound 2w5b Human Nek2 kinase ATPgammaS-bound 2w5h Human Nek2 kinase ATPgammaS-bound 2w7x Cellular inhibition of checkpoint kinase 2 and potentiation of cytotoxic drugs by novel Chk2 inhibitor PV1019 2w96 Crystal Structure of CDK4 in complex with a D-type cyclin 2w99 Crystal Structure of CDK4 in complex with a D-type cyclin 2w9f Crystal Structure of CDK4 in complex with a D-type cyclin 2w9z Crystal Structure of CDK4 in complex with a D-type cyclin 2waj Crystal structure of human Jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitor 2wei Crystal structure of the kinase domain of Cryptosporidium parvum calcium dependent protein kinase in complex with 3-MB-PP1 2wel Crystal structure of SU6656-bound calcium/calmodulin-dependent protein kinase II delta in complex with calmodulin 2wev Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design 2wfy Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design 2whb Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design 2wih STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 2wip STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO- 1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID 2wma Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin A 2wmb Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin A 2wmq Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wmr Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wms Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wmt Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wmu Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wmv Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wmw Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wmx Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2wnt Crystal Structure of the Human Ribosomal protein S6 kinase 2wo6 Human Dual-Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A in complex with a consensus substrate peptide 2wpa Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK Inhibitor Suitable for Intravenous Dosing 2wqe Structure of S155R Aurora-A somatic mutant 2wqm Structure of apo human Nek7 2wqn Structure of ADP-bound human Nek7 2wqo STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950 2wtc CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR 2wtd Crystal structure of Chk2 in complex with an inhibitor 2wti CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR 2wtj CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR 2wtk Structure of the heterotrimeric LKB1-STRADalpha-MO25alpha complex 2wtv Aurora-A Inhibitor Structure 2wtw Aurora-A Inhibitor Structure (2nd crystal form) 2wu6 Crystal Structure of the Human CLK3 in complex with DKI 2wu7 Crystal Structure of the Human CLK3 in complex with V25 2wxv Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor 2wzj Catalytic and UBA domain of kinase MARK2/(Par-1) K82R, T208E double mutant 2x0g X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX 2x1n Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design 2x39 Structure of 4-Amino-N-(4-chlorobenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin- 4-yl)piperidine-4-carboxamide bound to PKB 2x4f The Crystal Structure of the human myosin light chain kinase LOC340156. 2x4z Crystal Structure of the Human p21-Activated Kinase 4 in Complex with PF-03758309 2x6d Aurora-A bound to an inhibitor 2x6e Aurora-A bound to an inhibitor 2x7f Crystal structure of the kinase domain of human Traf2- and Nck- interacting Kinase with Wee1Chk1 inhibitor 2x81 STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054 2x8d Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration 2x8e Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration 2x8i Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration 2x9e HUMAN MPS1 IN COMPLEX WITH NMS-P715 2xbj Crystal Structure of Chk2 in complex with an inhibitor 2xch Crystal structure of PDK1 in complex with a pyrazoloquinazoline inhibitor 2xck Crystal structure of PDK1 in complex with a pyrazoloquinazoline inhibitor 2xey Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2xez Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2xf0 Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2xh5 Structure of 4-(4-tert-Butylbenzyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4- yl)piperidin-4-amine bound to PKB 2xik Structure of Human YSK1 (Yeast Sps1-Ste20-related Kinase 1) 2xix Protein kinase Pim-1 in complex with fragment-1 from crystallographic fragment screen 2xiy Protein kinase Pim-1 in complex with fragment-2 from crystallographic fragment screen 2xiz Protein kinase Pim-1 in complex with fragment-3 from crystallographic fragment screen 2xj0 Protein kinase Pim-1 in complex with fragment-4 from crystallographic fragment screen 2xj1 Protein kinase Pim-1 in complex with small molecule inibitor 2xj2 Protein kinase Pim-1 in complex with small molecule inhibitor 2xk3 Structure of Nek2 bound to Aminopyrazine compound 35 2xk4 Structure of Nek2 bound to aminopyrazine compound 17 2xk6 Structure of Nek2 bound to aminopyrazine compound 36 2xk7 Structure of Nek2 bound to aminopyrazine compound 23 2xk8 Structure of Nek2 bound to aminopyrazine compound 15 2xk9 Structural analysis of checkpoint kinase 2 (Chk2) in complex with inhibitor PV1533 2xkc Structure of Nek2 bound to aminopyrazine compound 14 2xkd Structure of Nek2 bound to aminopyrazine compound 12 2xke Structure of Nek2 bound to Aminipyrazine Compound 5 2xkf Structure of Nek2 bound to aminopyrazine compound 2 2xm8 Co-crystal structure of a small molecule inhibitor bound to the kinase domain of Chk2 2xm9 Structure of a small molecule inhibitor with the kinase domain of Chk2 2xmy Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents 2xnb Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents 2xne Structure of Aurora-A bound to an imidazopyrazine inhibitor 2xng Structure of Aurora-A bound to a selective imidazopyrazine inhibitor 2xnm Structure of NEK2 bound to CCT 2xnn Structure of Nek2 bound to CCT242430 2xno Structure of Nek2 bound to CCT243779 2xnp Structure of Nek2 bound to CCT244858 2xru AURORA-A T288E COMPLEXED WITH PHA-828300 2xrw Linear binding motifs for JNK and for calcineurin antagonistically control the nuclear shuttling of NFAT4 2xs0 Linear binding motifs for JNK and for calcineurin antagonistically control the nuclear shuttling of NFAT4 2xuu Crystal structure of a DAP-kinase 1 mutant 2xzs Death associated protein kinase 1 residues 1-312 2y0a Structure of DAPK1 construct residues 1-304 2y4i KSR2-MEK1 heterodimer 2y4p Dimeric structure of DAPK-1 catalytic domain 2y7j Structure of human phosphorylase kinase, gamma 2 2y8o Crystal structure of human p38alpha complexed with a MAPK docking peptide 2y9q Crystal structure of human ERK2 complexed with a MAPK docking peptide 2ya9 Crystal structure of the autoinhibited form of mouse DAPK2 2yaa Crystal structure of the autoinhibited form of mouse DAPK2 in complex with ATP 2yab Crystal structure of the autoinhibited form of mouse DAPK2 in complex with AMP 2yac Crystal structure of Polo-like kinase 1 in complex with NMS-P937 2yak Structure of death-associated protein Kinase 1 (dapk1) in complex with a ruthenium octasporine ligand (OSV) 2ycf Crystal Structure of Checkpoint Kinase 2 in complex with Inhibitor PV1531 2ycq Crystal structure of checkpoint kinase 2 in complex with inhibitor PV1115 2ycr Crystal structure of checkpoint kinase 2 in complex with inhibitor PV976 2ycs Crystal structure of checkpoint kinase 2 in complex with PV788 2ydi Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas 2ydj Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas 2ydk Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thiophene Carboxamide Ureas 2yer Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors 2yex Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors 2yiq Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1322 2yir Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1352 2yis triazolopyridine inhibitors of p38 kinase. 2yit Structural analysis of checkpoint kinase 2 in complex with PV1162, a novel inhibitor 2yiw triazolopyridine inhibitors of p38 kinase 2yix Triazolopyridine Inhibitors of p38 2ym3 Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2ym4 Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2ym5 Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2ym6 Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2ym7 Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2ym8 Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors 2ywp Crystal Structure of CHK1 with a Urea Inhibitor 2yza Crystal structure of kinase domain of Human 5'-AMP-activated protein kinase alpha-2 subunit mutant (T172D) 2z7l Unphosphorylated Mitogen Activated Protein Kinase ERK2 in Complex with (4-{[5-Carbamoyl-4-(3-Methylanilino)Pyrimidin 2-Yl]Amino}Phenyl)Acetic Acid 2z7q Crystal structure of the N-terminal kinase domain of human RSK-1 bound to AMP-PCP 2z7r Crystal Structure of the N-terminal Kinase Domain of Human RSK1 bound to Staurosporine 2z7s Crystal Structure of the N-terminal Kinase Domain of Human RSK1 bound to Purvalnol A 2zaz Crystal structure of P38 in complex with 4-anilino quinoline inhibitor 2zb0 Crystal structure of P38 in complex with biphenyl amide inhibitor 2zb1 Crystal structure of P38 in complex with biphenyl amide inhibitor 2zdt Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor 2zdu Crystal Structure of human JNK3 complexed with an isoquinolone inhibitor 2zjw Crystal structure of human CK2 alpha complexed with Ellagic acid 2zmc Crystal structure of human mitotic checkpoint kinase Mps1 catalytic domain apo form 2zmd Crystal structure of human Mps1 catalytic domain T686A mutant in complex with SP600125 inhibitor 2zoq Structural dissection of human mitogen-activated kinase ERK1 2zv2 Crystal structure of human calcium/calmodulin-dependent protein kinase kinase 2, beta, CaMKK2 kinase domain in complex with STO-609 3a2c Crystal structure of a pyrazolopyrimidine inhibitor complex bound to MAPKAP Kinase-2 (MK2) 3a60 Crystal structure of unphosphorylated p70S6K1 (Form I) 3a61 Crystal structure of unphosphorylated p70S6K1 (Form II) 3a62 Crystal structure of phosphorylated p70S6K1 3a7f Human MST3 kinase 3a7g Human MST3 kinase 3a7h Human MST3 kinase in complex with ATP 3a7i Human MST3 kinase in complex with adenine 3a7j Human MST3 kinase in complex with MnADP 3a8w Crystal Structure of PKCiota kinase domain 3a8x Crystal Structure of PKCiota kinase domain 3a99 Structure of PIM-1 kinase crystallized in the presence of P27KIP1 Carboxy-terminal peptide 3ag9 Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1012 3agl Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1039 3agm Complex of PKA with the bisubstrate protein kinase inhibitor ARC-670 3aln Crystal Structure of human non-phosphorylated MKK4 kinase domain complexed with AMP-PNP 3alo Crystal structure of human non-phosphorylated MKK4 kinase domain ternary complex with AMP-PNP and p38 peptide 3ama Protein kinase A sixfold mutant model of Aurora B with inhibitor JNJ-7706621 3amb Protein kinase A sixfold mutant model of Aurora B with inhibitor VX-680 3amy Crystal structure of human CK2 alpha complexed with apigenin 3anq human DYRK1A/inhibitor complex 3anr human DYRK1A/harmine complex 3aqv Human AMP-activated protein kinase alpha 2 subunit kinase domain (T172D) complexed with compound C 3at2 Crystal structure of CK2alpha 3at3 Crystal structure of CK2alpha with pyradine derivative 3at4 Crystal structure of CK2alpha with pyradine derivertive 3axw Crystal structure of human CK2alpha complexed with a potent inhibitor 3be9 Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities 3bgp Human Pim-1 complexed with a benzoisoxazole inhibitor VX1 3bgq Human Pim-1 kinase in complex with an triazolo pyridazine inhibitor VX2 3bgz Human Pim-1 kinase in complex with diphenyl indole inhibitor VX3 3bhh Crystal structure of human calcium/calmodulin-dependent protein kinase IIB isoform 1 (CAMK2B) 3bht Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3 3bhu Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5 3bhv Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B 3bhy Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with a beta-carboline ligand 3blh Crystal Structure of Human CDK9/cyclinT1 3blq Crystal Structure of Human CDK9/cyclinT1 in Complex with ATP 3blr Crystal Structure of Human CDK9/cyclinT1 in complex with Flavopiridol 3bqc High pH-value crystal structure of emodin in complex with the catalytic subunit of protein kinase CK2 3bqr Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with an imidazo-pyridazine ligand 3bv2 Morpholino pyrrolotriazine P38 Alpha map kinase inhibitor compound 30 3bv3 Morpholino pyrrolotriazine P38 Alpha Map Kinase inhibitor compound 2 3bwf Crystal structure of the human Pim1 in complex with an osmium compound 3bwj Complex of PKA with the bisubstrate protein kinase inhibitor lead compound Arc-1034 3bx5 P38 alpha map kinase complexed with BMS-640994 3c0g CASK CaM-Kinase Domain- 3'-AMP complex, P1 form 3c0h CASK CaM-Kinase Domain- AMPPNP complex, P1 form 3c0i CASK CaM-Kinase Domain- 3'-AMP complex, P212121 form 3c13 Low pH-value crystal structure of emodin in complex with the catalytic subunit of protein kinase CK2 3c4e Pim-1 Kinase Domain in Complex with 3-aminophenyl-7-azaindole 3c4w Crystal Structure of G protein coupled receptor kinase 1 bound to ATP and magnesium chloride at 2.7A 3c4x Crystal Structure of G protein coupled receptor kinase 1 bound to ATP and magnesium chloride at 2.9A 3c4y Crystal Structure of Apo form of G protein coupled receptor kinase 1 at 7.51A 3c4z Crystal structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 1.84A 3c50 Crystal Structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 2.6A 3c51 Crystal structure of G protein coupled receptor kinase 1 bound to ADP and magnesium chloride at 3.55A 3c5u P38 ALPHA map kinase complexed with a benzothiazole based inhibitor 3c9w Crystal Structure of ERK-2 with hypothemycin covalently bound 3cek Crystal structure of human dual specificity protein kinase (TTK) 3cgf IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding 3cgo IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine binding 3cik Human GRK2 in Complex with Gbetagamma subunits 3ckw Crystal structure of sterile 20-like kinase 3 (MST3, STK24) 3ckx Crystal structure of sterile 20-like kinase 3 (MST3, STK24) in complex with staurosporine 3coh Crystal structure of Aurora-A in complex with a pentacyclic inhibitor 3coi Crystal structure of p38delta kinase 3cok Crystal structure of PLK4 kinase 3com Crystal structure of Mst1 kinase 3cqu Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor 3cqw Crystal Structure of Akt-1 complexed with substrate peptide and inhibitor 3ctq Structure of MAP kinase p38 in complex with a 1-o-tolyl-1,2,3-triazole-4-carboxamide 3cxw Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a beta carboline ligand I 3cy2 Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a beta carboline ligand II 3cy3 Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and the JNK inhibitor V 3d0e Crystal structure of human Akt2 in complex with GSK690693 3d14 Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)-ethyl]- thiazol-2-yl}-3-(3-trifluoromethyl-phenyl)-urea 3d15 Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-(3-chloro-phenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)- ethyl]-thiazol-2-yl}-urea [SNS-314] 3d2i Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with 1-{5-[2-(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamino)-ethyl]-thiazol-2-yl}-3-(3-trifluoromethyl-phenyl)-urea 3d2k Crystal structure of mouse Aurora A (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with [7-(2-{2-[3-(3-chloro-phenyl)-ureido]-thiazol-5-yl}-ethylamino)-pyrazolo[4,3-d]pyrimidin-1-yl]-acetic acid 3d5u Crystal structure of a wildtype Polo-like kinase 1 (Plk1) catalytic domain. 3d5v Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain. 3d5w Crystal structure of a phosphorylated Polo-like kinase 1 (Plk1) catalytic domain in complex with ADP. 3d5x Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with wortmannin. 3d7z Crystal Structure of P38 Kinase in Complex with a biphenyl amide inhibitor 3d83 Crystal structure of P38 kinase in complex with a biphenyl amide inhibitor 3d9v CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI-METHYLATED VARIANT OF FASUDIL 3da6 Crystal Structure of human JNK3 complexed with N-(3-methyl-4-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)naphthalen-1-yl)-1H-benzo[d]imidazol-2-amine 3dae Crystal structure of phosphorylated SNF1 kinase domain 3daj Crystal structure of Aurora A complexed with an inhibitor discovered through site-directed dynamic tethering 3dak Crystal Structure of Domain-Swapped OSR1 kinase domain 3db6 Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 902 3db8 Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 041 3dbc Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 257 3dbd Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 094 3dbe Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 557 3dbf Crystal structure of an activated (Thr->Asp) Polo-like kinase 1 (Plk1) catalytic domain in complex with Compound 562 3dbq Crystal structure of TTK kinase domain 3dcv Crystal structure of human Pim1 kinase complexed with 4-(4-hydroxy-3-methyl-phenyl)-6-phenylpyrimidin-2(1H)-one 3ddp Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8 3ddq Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine 3dfa Crystal structure of kinase domain of calcium-dependent protein kinase cgd3_920 from Cryptosporidium parvum 3dfc Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain with AMPPNP 3dgk Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain 3dj5 Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 290. 3dj6 Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 823. 3dj7 Crystal structure of the mouse Aurora-A catalytic domain (Asn186->Gly, Lys240->Arg, Met302->Leu) in complex with Compound 130. 3dls Crystal structure of human PAS kinase bound to ADP 3dnd cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24 3dne cAMP-dependent protein kinase PKA catalytic subunit with PKI-5-24 3dog Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1 3ds6 P38 complex with a phthalazine inhibitor 3dt1 P38 Complexed with a quinazoline inhibitor 3du8 Crystal structure of GSK-3 beta in complex with NMS-869553A 3dv3 MEK1 with PF-04622664 Bound 3dxn Crystal structure of the calcium-dependent kinase from toxoplasma gondii, 541.m00134, kinase domain. 3dy7 X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP 3e3b Crystal structure of catalytic subunit of human protein kinase CK2alpha prime with a potent indazole-derivative inhibitor 3e3p Glycogen synthase kinase from Leishmania major 3e5a Crystal structure of Aurora A in complex with VX-680 and TPX2 3e7o Crystal Structure of JNK2 3e87 Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors 3e88 Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors 3e8c Crystal structures of the kinase domain of PKA in complex with ATP-competitive inhibitors 3e8d Crystal structures of the kinase domain of AKT2 in complex with ATP-competitive inhibitors 3e8e Crystal structures of the kinase domain of PKA in complex with ATP-competitive inhibitors 3e8n X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) complexed with a potent inhibitor RDEA119 and MgATP 3e92 Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor 3e93 Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor 3eb0 Crystal Structure of cgd4_240 from cryptosporidium Parvum in complex with indirubin E804 3efw Structure of AuroraA with pyridyl-pyrimidine urea inhibitor 3eh9 Crystal structure of death associated protein kinase complexed with ADP 3eha Crystal structure of death associated protein kinase complexed with AMPPNP 3eid CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor 3ej1 CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor 3elj Jnk1 complexed with a bis-anilino-pyrrolopyrimidine inhibitor. 3enm The structure of the MAP2K MEK6 reveals an autoinhibitory dimer 3eoc Cdk2/CyclinA complexed with a imidazo triazin-2-amine 3eqb X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a complex with ligand and MgATP 3eqc X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with compound 1, ATP-GS AND MG2P 3eqd X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with ATP-GS and MG2P 3eqf X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with K252A and MG2P 3eqg X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with PD, ADP AND MG2P 3eqh X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a ternary complex with U0126, ADP and MG2P 3eqi X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in a binary complex with ADP and MG2P 3erk THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025 3ezr CDK-2 with indazole inhibitor 17 bound at its active site 3ezv CDK-2 with indazole inhibitor 9 bound at its active site 3f2a Crystal structure of human Pim-1 in complex with DAPPA 3f3z Crystal structure of Cryptosporidium parvum calcium dependent protein kinase cgd7_1840 in presence of indirubin E804 3f5g Crystal structure of death associated protein kinase in complex with ADP and Mg2+ 3f5u Crystal structure of the death associated protein kinase in complex with AMPPNP and Mg2+ 3f5x CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site 3f61 Crystal Structure of M. tuberculosis PknB Leu33Asp/Val222Asp double mutant in complex with ADP 3f69 Crystal structure of the Mycobacterium tuberculosis PknB mutant kinase domain in complex with KT5720 3f7z X-ray Co-Crystal Structure of Glycogen Synthase Kinase 3beta in Complex with an Inhibitor 3f88 glycogen synthase Kinase 3beta inhibitor complex 3f9n Crystal structure of chk1 kinase in complex with inhibitor 38 3fc1 Crystal structure of p38 kinase bound to pyrimido-pyridazinone inhibitor 3fc2 PLK1 in complex with BI6727 3fdn Structure-based drug design of novel Aurora kinase A inhibitors: Structure basis for potency and specificity 3fe3 Crystal structure of the kinase MARK3/Par-1: T211A-S215A double mutant 3fhi Crystal structure of a complex between the catalytic and regulatory (RI{alpha}) subunits of PKA 3fhr High resolution crystal structure of mitogen-activated protein kinase-activated protein kinase 3 (MK3)-inhibitor complex 3fi2 Crystal structure of JNK3 with amino-pyrazole inhibitor, SR-3451 3fi3 Crystal structure of JNK3 with indazole inhibitor, SR-3737 3fi4 P38 kinase crystal structure in complex with RO4499 3fjq Crystal structure of cAMP-dependent protein kinase catalytic subunit alpha in complex with peptide inhibitor PKI alpha (6-25) 3fkl P38 kinase crystal structure in complex with RO9552 3fkn P38 kinase crystal structure in complex with RO7125 3fko P38 kinase crystal structure in complex with RO3668 3fl4 P38 kinase crystal structure in complex with RO5634 3fl5 Protein kinase CK2 in complex with the inhibitor Quinalizarin 3fln P38 kinase crystal structure in complex with R1487 3flq P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-((s)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8h-pyrido[2,3-d]pyrimidin 3fls P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-2-((R)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 3flw P38 kinase crystal structure in complex with pamapimod 3fly P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-isopropylamino-8-methyl-8h-pyrido[2,3-d]pyrimidin-7-one 3flz P38 kinase crystal structure in complex WITH 8-Methyl-6-phenoxy-2-(tetrahydro-pyran-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 3fme Crystal Structure of Human Mitogen-Activated Protein Kinase Kinase 6 (MEK6) Activated Mutant (S207D, T211D) 3fmh P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((R)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 3fmj P38 kinase crystal structure in complex with 4-(5-Methyl-3-phenyl-isoxazol-4-yl)-pyrimidin-2-ylamine 3fmk P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((S)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one 3fml P38 kinase crystal structure in complex with RO6224 3fmm P38 kinase crystal structure in complex with RO6226 3fmn P38 kinase crystal structure in complex with RO2530 3fpm Crystal Structure of a Squarate Inhibitor bound to MAPKAP Kinase-2 3fsf P38 kinase crystal structure in complex with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one 3fsk P38 kinase crystal structure in complex with RO6257 3fv8 JNK3 bound to piperazine amide inhibitor, SR2774. 3fwq Inactive conformation of human protein kinase CK2 catalytic subunit 3fxw High resolution crystal structure of mitogen-activated protein kinase-activated protein kinase 3/inhibitor 2 complex 3fxz Crystal structure of PAK1 kinase domain with ruthenium complex lambda-FL172 3fy0 Crystal structure of PAK1 kinase domain with ruthenium complex DW1 3fyj Crystal structure of an optimzied benzothiophene inhibitor bound to MAPKAP Kinase-2 (MK-2) 3fyk Crystal structure of a benzthiophene lead bound to MAPKAP Kinase-2 (MK-2) 3fz1 Crystal structure of a benzthiophene inhibitor bound to human Cyclin-dependent Kinase-2 (CDK-2) 3g33 Crystal structure of CDK4/cyclin D3 3g51 Structural diversity of the active conformation of the N-terminal kinase domain of p90 ribosomal S6 kinase 2 3g90 JNK-3 bound to (Z)-5-fluoro-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)indolin-2-one 3g9l JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-styrylindolin-2-one 3g9n JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-phenylindolin-2-one 3gb2 GSK3beta inhibitor complex 3gbz Structure of the CMGC CDK Kinase from Giardia lamblia 3gc0 Structure of the CMGC CDK Kinase from Giardia lamblia in complex with AMP 3gc7 The structure of p38alpha in complex with a dihydroquinazolinone 3gc8 The structure of p38beta C162S in complex with a dihydroquinazolinone 3gc9 The structure of p38beta C119S, C162S in complex with a dihydroquinazolinone inhibitor 3gcp Human P38 MAP Kinase in Complex with SB203580 3gcq Human P38 MAP kinase in complex with RL45 3gcs Human P38 MAP kinase in complex with Sorafenib 3gcu Human P38 MAP kinase in complex with RL48 3gcv Human P38 MAP Kinase in Complex with RL62 3gfe Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridinone Inhibitor 3gfw Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a pyrolo-pyridin ligand 3ggf Crystal structure of human Serine/threonine-protein kinase MST4 in complex with an quinazolin 3gi3 Crystal structure of a N-Phenyl-N'-Naphthylurea analog in complex with p38 MAP kinase 3gok Binding site mapping of protein ligands 3gp0 Crystal Structure of Human Mitogen Activated Protein Kinase 11 (p38 beta) in complex with Nilotinib 3gu4 Crystal structure of DAPKQ23V-AMPPNP 3gu5 Crystal structure of DAPKQ23V-AMPPNP-Mg2+ 3gu6 Crystal structure of DAPKQ23V-ADP 3gu7 Crystal structure of DAPKQ23V-ADP-Mg2+ 3gu8 Crystal structure of DAPKL93G with N6-cyclopentyladenosine 3gub Crystal structure of DAPKL93G complexed with N6-(2-Phenylethyl)adenosine 3h0y Aurora A in complex with a bisanilinopyrimidine 3h0z Aurora A in complex with a bisanilinopyrimidine 3h10 Aurora A inhibitor complex 3h30 Crystal structure of the catalytic subunit of human protein kinase CK2 with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole 3h4j crystal structure of pombe AMPK KDAID fragment 3h9f Crystal Structure of Human Dual Specificity Protein Kinase (TTK) in complex with a pyrimido-diazepin ligand 3h9o Phosphoinositide-dependent protein kinase 1 (PDK-1) in complex with compound 9 3ha6 Crystal structure of aurora A in complex with TPX2 and compound 10 3ha8 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/Compound 14b 3hdm Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 1 3hdn Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 2 3hec P38 in complex with Imatinib 3heg P38 in complex with Sorafenib 3hko Crystal structure of a cdpk kinase domain from cryptosporidium Parvum, cgd7_40 3hl7 Crystal Structure of Human p38alpha complexed with SD-0006 3hll Crystal Structure of Human p38alpha complexed with PH-797804 3hmn Crystal structure of human Mps1 catalytic domain in complex with ATP 3hmo Crystal structure of human Mps1 catalytic domain in complex with the inhibitor staurosporine 3hmp Crystal structure of human Mps1 catalytic domain in complex with a quinazolin ligand Compound 4 3hp2 Crystal Structure of Human p38alpha complexed with a pyridinone compound 3hp5 Crystal Structure of Human p38alpha complexed with a pyrimidopyridazinone compound 3hrb p38 kinase Crystal structure in complex with small molecule inhibitor 3hrc Crystal structure of a mutant of human PDK1 Kinase domain in complex with ATP 3hrf Crystal structure of Human PDK1 kinase domain in complex with an allosteric activator bound to the PIF-pocket 3hub Human p38 MAP Kinase in Complex with Scios-469 3huc Human p38 MAP Kinase in Complex with RL40 3hv3 Human p38 MAP Kinase in Complex with RL49 3hv4 Human p38 MAP Kinase in Complex with RL51 3hv5 Human p38 MAP Kinase in Complex with RL24 3hv6 Human p38 MAP Kinase in Complex with RL39 3hv7 Human p38 MAP Kinase in Complex with RL38 3hvc Crystal structure of human p38alpha MAP kinase 3hx4 Crystal structure of CDPK1 of Toxoplasma gondii, TGME49_101440, in presence of calcium 3hyh Crystal structure of the protein kinase domain of yeast AMP-activated protein kinase Snf1 3hzt Crystal structure of Toxoplasma gondii CDPK3, TGME49_105860 3i4b Crystal structure of GSK3b in complex with a pyrimidylpyrrole inhibitor 3i5z Crystal structure of ERK2 bound to (S)-N-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-1H-pyrrole-2-carboxamide 3i60 Crystal structure of ERK2 bound to (S)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-N-(2-hydroxy-1-phenylethyl)-1H-pyrrole-2-carboxamide 3i6u Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase 3i6w Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase 3i79 Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) 3i7b Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NM-PP1 3i7c Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor NA-PP2 3idb Crystal structure of (108-268)RIIb:C holoenzyme of cAMP-dependent protein kinase 3idc Crystal structure of (102-265)RIIb:C holoenzyme of cAMP-dependent protein kinase 3iec Helicobacter pylori CagA Inhibits PAR1/MARK Family Kinases by Mimicking Host Substrates 3ig7 Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2 3igg Novel CDK-5 inhibitors - crystal structure of inhibitor EFQ with CDK-2 3igo Crystal structure of Cryptosporidium parvum CDPK1, cgd3_920 3ion PDK1 in complex with Compound 8h 3iop PDK-1 in complex with the inhibitor Compound-8i 3iph Crystal structure of p38 in complex with a biphenylamide inhibitor 3is5 Crystal structure of CDPK kinase domain from toxoplasma Gondii, TGME49_018720 3itz Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridazine Inhibitor 3iw4 Crystal structure of PKC alpha in complex with NVP-AEB071 3iw5 Human p38 MAP Kinase in Complex with an Indole Derivative 3iw6 Human p38 MAP Kinase in Complex with a Benzylpiperazin-Pyrrol 3iw7 Human p38 MAP Kinase in Complex with an Imidazo-pyridine 3iw8 Structure of Inactive Human p38 MAP Kinase in Complex with a Thiazole-Urea 3j4q Pseudo-atomic model of the AKAP18-PKA complex in a bent conformation derived from electron microscopy 3j4r Pseudo-atomic model of the AKAP18-PKA Complex in a linear conformation derived from electron microscopy 3jpv Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a pyrrolo[2,3-a]carbazole ligand 3juh Crystal structure of a mutant of human protein kinase CK2alpha with altered cosubstrate specificity 3jvr Characterization of the Chk1 allosteric inhibitor binding site 3jvs Characterization of the Chk1 allosteric inhibitor binding site 3jxw Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors 3jy0 Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors 3jya Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as Potent, Highly Selective and Orally Bioavailable Pim Kinases Inhibitors 3k2l Crystal Structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (DYRK2) 3k3i p38alpha bound to novel DGF-out compound PF-00215955 3k3j P38alpha bound to novel DFG-out compound PF-00416121 3k5u Identification, SAR Studies and X-ray Cocrystal Analysis of a Novel Furano-pyrimidine Aurora Kinase A Inhibitor 3ka0 MK2 complex with inhibitor 6-(5-(2-aminopyrimidin-4-ylamino)-2-hydroxyphenyl)-N-methylbenzo[b]thiophene-2-carboxamide 3kb7 Crystal structure of Polo-like kinase 1 in complex with a pyrazoloquinazoline inhibitor 3kc3 MK2 complexed to inhibitor N4-(7-(benzofuran-2-yl)-1H-indazol-5-yl)pyrimidine-2,4-diamine 3kf7 Crystal Structure of Human p38alpha Complexed With a Triazolopyrimidine compound 3kga Crystal structure of MAPKAP kinase 2 (MK2) complexed with a potent 3-aminopyrazole ATP site inhibitor 3kk8 CaMKII Substrate Complex A 3kk9 CaMKII Substrate Complex B 3kkv Structure of PKA with a protein Kinase B-selective inhibitor. 3kl8 CaMKIINtide Inhibitor Complex 3kn5 Crystal structure of the C-terminal kinase domain of msk1 in complex with AMP-PNP 3kn6 Crystal structure of the C-terminal kinase domain of MSK1 3kq7 Structure of human p38alpha with N-[4-methyl-3-(6-{[2-(1-methylpyrrolidin-2-yl)ethyl]amino}pyridine-3-amido)phenyl]-2-(morpholin-4-yl)pyridine-4-carboxamide 3krw Human GRK2 in complex with Gbetgamma subunits and balanol (soak) 3krx Human GRK2 in complex with Gbetgamma subunits and balanol (co-crystal) 3ku2 Crystal Structure of inactivated form of CDPK1 from toxoplasma gondii, TGME49.101440 3kvw Crystal Structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (DYRK2) in complex with an indirubin ligand 3kvx JNK3 bound to aminopyrimidine inhibitor, SR-3562 3kxg Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor 3,4,5,6,7-pentabromo-1H-indazole (K64) 3kxh Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor (2-dymethylammino-4,5,6,7-tetrabromobenzoimidazol-1yl-acetic acid (K66) 3kxm Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor K74 3kxn Crystal structure of Z. mays CK2 kinase alpha subunit in complex with the inhibitor tetraiodobenzimidazole (K88) 3l1s 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3 3l8s Human p38 MAP Kinase in Complex with CP-547632 3l8x P38 alpha kinase complexed with a pyrazolo-pyrimidine based inhibitor 3l9l Crystal structure of pka with compound 36 3l9m Crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 18 3l9n crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 27 3lau Crystal Structure of Aurora2 kinase in complex with a GSK3beta inhibitor 3le6 The structure of cyclin dependent kinase 2 (CKD2) with a pyrazolobenzodiazepine inhibitor 3lfa Human p38 MAP Kinase in Complex with Dasatinib 3lfb Human p38 MAP Kinase in Complex with RL98 3lfc Human p38 MAP Kinase in Complex with RL99 3lfd Human p38 MAP Kinase in Complex with RL113 3lfe Human p38 MAP Kinase in Complex with RL116 3lff Human p38 MAP Kinase in Complex with RL166 3lfn Crystal structure of CDK2 with SAR57, an aminoindazole type inhibitor 3lfq Crystal structure of CDK2 with SAR60, an aminoindazole type inhibitor 3lfs Crystal structure of CDK2 with SAR37, an aminoindazole type inhibitor 3lhj Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridinone Inhibitor. 3lij Crystal structure of full length CpCDPK3 (cgd5_820) in complex with Ca2+ and AMPPNP 3llt Crystal structure of PF14_0431, kinase domain. 3lm0 Crystal Structure of human Serine/Threonine Kinase 17B (STK17B) 3lm5 Crystal Structure of human Serine/Threonine Kinase 17B (STK17B) in complex with Quercetin 3lq5 Structure of CDK9/CyclinT in complex with S-CR8 3m11 Crystal Structure of Aurora A Kinase complexed with inhibitor 3m1s Structure of Ruthenium Half-Sandwich Complex Bound to Glycogen Synthase Kinase 3 3m2w Crystal structure of MAPKAK kinase 2 (MK2) complexed with a spiroazetidine-tetracyclic ATP site inhibitor 3m42 Crystal structure of MAPKAP kinase 2 (MK2) complexed with a tetracyclic ATP site inhibitor 3ma3 Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a naphtho-difuran ligand 3ma6 Crystal structure of kinase domain of TgCDPK1 in presence of 3BrB-PP1 3mb6 Human CK2 catalytic domain in complex with a difurane derivative inhibitor (CPA) 3mb7 Human CK2 catalytic domain in complex with a difurane derivative inhibitor (AMR) 3mbl Crystal Structure of the human mitogen-activated protein kinase kinase 1 (MEK 1) in complex with ligand and MgADP 3mfr CASK-4M CaM Kinase Domain, native 3mfs CASK-4M CaM Kinase Domain, AMPPNP 3mft CASK-4M CaM Kinase Domain, Mn2+ 3mfu CASK-4M CaM Kinase Domain, AMPPNP-Mn2+ 3mgy Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state 3mh0 Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state 3mh1 Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state 3mh2 Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state 3mh3 Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state 3mi9 Crystal structure of HIV-1 Tat complexed with human P-TEFb 3mia Crystal structure of HIV-1 Tat complexed with ATP-bound human P-TEFb 3mn3 An inhibited conformation for the protein kinase domain of the Saccharomyces cerevisiae AMPK homolog Snf1 3mpa Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3mpt Crystal structure of P38 kinase in complex with a pyrrole-2-carboxamide inhibitor 3mtl Crystal structure of the PCTAIRE1 kinase in complex with Indirubin E804 3mv5 Crystal structure of Akt-1-inhibitor complexes 3mvh Crystal structure of Akt-1-inhibitor complexes 3mvj Human cyclic AMP-dependent protein kinase PKA inhibitor complex 3mvl P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7K 3mvm P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7V 3mw1 p38 kinase Crystal structure in complex with small molecule inhibitor 3mwu Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor RM-1-95 3my1 Structure of CDK9/cyclinT1 in complex with DRB 3my5 CDk2/cyclinA in complex with DRB 3myg Aurora A Kinase complexed with SCH 1473759 3n51 Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumped kinase inhibitor RM-1-95 3n9x Crystal structure of Map Kinase from plasmodium berghei, PB000659.00.0 3nax PDK1 in complex with inhibitor MP7 3nay PDK1 in complex with inhibitor MP6 3ncg Activated Calcium-Dependent Protein Kinase 1 from Cryptosporidium parvum (CpCDPK1) in complex with bumped kinase inhibitor NM-PP1 3ncz X-Ray Co-structure of Rho-Associated Protein Kinase (ROCK1) with a potent 2H-isoquinolin-1-one inhibitor 3ndm Crystal structure of Rho-Associated Protein Kinase (ROCK1) with a potent isoquinolone derivative 3new p38-alpha complexed with Compound 10 3nga Human CK2 catalytic domain in complex with CX-4945 3nie Crystal Structure of PF11_0147 3niz Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with ADP bound. 3nlb Novel kinase profile highlights the temporal basis of context dependent checkpoint pathways to cell death 3nnu Crystal structure of P38 alpha in complex with DP1376 3nnv Crystal structure of P38 alpha in complex with DP437 3nnw Crystal structure of P38 alpha in complex with DP802 3nnx Crystal structure of phosphorylated P38 alpha in complex with DP802 3npc Crystal structure of JNK2 complexed with BIRB796 3nr9 Structure of human CDC2-like kinase 2 (CLK2) 3nrm Imidazo[1,2-a]pyrazine-based Aurora Kinase Inhibitors 3ns9 Crystal structure of CDK2 in complex with inhibitor BS-194 3nsz Human CK2 catalytic domain in complex with AMPPN 3nun phosphoinositide-dependent kinase-1 (PDK1) with lead compound 3nup CDK6 (monomeric) in complex with inhibitor 3nus phosphoinositide-dependent kinase-1 (PDK1) with fragment8 3nuu phosphoinositide-dependent kinase-1 (PDK1) with fragment11 3nux CDK6 (monomeric) in complex with inhibitor 3nuy phosphoinositide-dependent kinase-1 (PDK1) with fragment17 3nww P38 Alpha kinase complexed with a 2-aminothiazol-5-yl-pyrimidine based inhibitor 3nx8 human cAMP dependent protein kinase in complex with phenol 3nyn Crystal Structure of G Protein-Coupled Receptor Kinase 6 in Complex with Sangivamycin 3nyo Crystal Structure of G Protein-Coupled Receptor Kinase 6 in Complex with AMP 3nyv Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with non-specific inhibitor WHI-P180 3o0g Crystal Structure of Cdk5:p25 in complex with an ATP analogue 3o17 Crystal Structure of JNK1-alpha1 isoform 3o2m Crystal Structure of JNK1-alpha1 isoform complex with a biaryl tetrazol (A-82118) 3o50 Crystal structure of benzamide 9 bound to AuroraA 3o51 Crystal structure of anthranilamide 10 bound to AuroraA 3o71 Crystal structure of ERK2/DCC peptide complex 3o7l Crystal Structure of phospholamban (1-19):PKA C-subunit:AMP-PNP:Mg2+ complex 3o8p Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3o8t Conformational plasticity of p38 MAP kinase DFG-motif mutants in response to inhibitor binding 3o8u Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3o96 Crystal Structure of Human AKT1 with an Allosteric Inhibitor 3obg Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding 3obj Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding 3oc1 Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding 3ocb Akt1 kinase domain with pyrrolopyrimidine inhibitor 3ocg P38 Alpha kinase complexed with a 5-amino-pyrazole based inhibitor 3od6 Crystal structure of p38alpha Y323T active mutant 3ody Crystal structure of p38alpha Y323Q active mutant 3odz Crystal structure of P38alpha Y323R active mutant 3oef Crystal structure of Y323F inactive mutant of p38alpha MAP kinase 3ofm Structure of a human CK2alpha prime, the paralog isoform of the catalytic subunit of protein kinase CK2 from Homo sapiens 3oht Crystal Structure of Salmo Salar p38alpha 3oog human cAMP-dependent protein kinase in complex with a small fragment 3ori Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 1) 3ork Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 2) 3orl Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 3) 3orn Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4987655 and MgAMP-PNP 3oro Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 4) 3orp Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 5) 3ort Mycobacterium tuberculosis PknB kinase domain L33D mutant (crystal form 6) 3orx PDK1 mutant bound to allosteric disulfide fragment inhibitor 1F8 3orz PDK1 mutant bound to allosteric disulfide fragment activator 2A2 3os3 Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP 3ot3 X-ray crystal structure of compound 22k bound to human Chk1 kinase domain 3ot8 X-ray crystal structure of compound 17r bound to human Chk1 kinase domain 3otu PDK1 mutant bound to allosteric disulfide fragment activator JS30 3ovv Human cAMP-dependent protein kinase in complex with an inhibitor 3ow3 Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors 3ow4 Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors 3owj Human CK2 catalytic domain in complex with a pyridocarbazole derivative inhibitor 3owk Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor 3owl Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor 3owp Human cAMP-dependent protein kinase in complex with an inhibitor 3oxi Design and Synthesis of Disubstituted Thiophene and Thiazole Based Inhibitors of JNK for the Treatment of Neurodegenerative Diseases 3oxt Human cAMP-dependent protein kinase in complex with an inhibitor 3oy1 Highly Selective c-Jun N-Terminal Kinase (JNK) 2 and 3 Inhibitors with In Vitro CNS-like Pharmacokinetic Properties 3oz6 Crystal structure of MapK from Cryptosporidium Parvum, cgd2_1960 3p0m Human cAMP-dependent protein kinase in complex with an inhibitor 3p4k The third conformation of p38a MAP kinase observed in phosphorylated p38a and in solution 3p5k P38 inhibitor-bound 3p78 P38 inhibitor-bound 3p79 P38 inhibitor-bound 3p7a p38 inhibitor-bound 3p7b p38 inhibitor-bound 3p7c p38 inhibitor-bound 3p9j Aurora A kinase domain with phthalazinone pyrazole inhibitor 3pa3 X-ray crystal structure of compound 70 bound to human CHK1 kinase domain 3pa4 X-ray crystal structure of compound 2a bound to human CHK1 kinase domain 3pa5 X-ray crystal structure of compound 1 bound to human CHK1 kinase domain 3pe1 Crystal structure of human protein kinase CK2 alpha subunit in complex with the inhibitor CX-4945 3pe2 Crystal structure of human protein kinase CK2 in complex with the inhibitor CX-5011 3pfq Crystal Structure and Allosteric Activation of Protein Kinase C beta II 3pg1 MAP kinase LmaMPK10 from Leishmania major (1.95 angs resolution) 3pg3 Human p38 MAP Kinase in Complex with RL182 3pj8 Structure of CDK2 in complex with a Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine. 3poo human cAMP-dependent protein kinase in complex with an inhibitor 3pp1 Crystal Structure of the Human Mitogen-activated protein kinase kinase 1 (MEK 1) in complex with ligand and MgATP 3ppz Crystal structure of CTR1 kinase domain in complex with staurosporine 3psc Bovine GRK2 in complex with Gbetagamma subunits 3ptg Design and Synthesis of a Novel, Orally Efficacious Tri-substituted Thiophene Based JNK Inhibitor 3pup Structure of Glycogen Synthase Kinase 3 beta (GSK3B) in complex with a ruthenium octasporine ligand (OS1) 3pvb Crystal structure of (73-244)RIa:C holoenzyme of cAMP-dependent Protein kinase 3pvg Crystal structure of Z. mays CK2 alpha subunit in complex with the inhibitor 4,5,6,7-tetrabromo-1-carboxymethylbenzimidazole (K68) 3pvu Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD101) 3pvw Bovine GRK2 in complex with Gbetagamma subunits and a selective kinase inhibitor (CMPD103A) 3pwd Crystal structure of maize CK2 in complex with NBC (Z1) 3pwy Crystal structure of an extender (SPD28345)-modified human PDK1 complex 2 3pxf CDK2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate 3pxq CDK2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate 3pxr Apo CDK2 crystallized from Jeffamine 3pxy CDK2 in complex with inhibitor JWS648 3pxz CDK2 ternary complex with JWS648 and ANS 3py0 CDK2 in complex with inhibitor SU9516 3py1 CDK2 ternary complex with SU9516 and ANS 3py3 Crystal structure of phosphorylated p38alpha MAP kinase 3pze JNK1 in complex with inhibitor 3pzh Crystal structure of maize CK2 alpha in complex with emodin at 1.92 A resolution 3q04 Crystal structure of the apo-form of human CK2 alpha at pH 8.5 3q3b 6-Amino-4-(pyrimidin-4-yl)pyridones: Novel Glycogen Synthase Kinase-3 Inhibitors 3q4z Structure of unphosphorylated PAK1 kinase domain 3q52 Structure of phosphorylated PAK1 kinase domain 3q53 Structure of phosphorylated PAK1 kinase domain in complex with ATP 3q5i Crystal Structure of PBANKA_031420 3q9w Crystal structure of human CK2 alpha in complex with emodin at pH 8.5 3q9x Crystal structure of human CK2 alpha in complex with emodin at pH 6.5 3q9y Crystal structure of human CK2 alpha in complex with Quinalizarin at pH 8.5 3q9z Crystal structure of human CK2 alpha in complex with Quinalizarin at pH 6.5 3qa0 Crystal structure of the apo-form of human CK2 alpha at pH 6.5 3qal Crystal Structure of Arg280Ala mutant of Catalytic subunit of cAMP-dependent Protein Kinase 3qam Crystal Structure of Glu208Ala mutant of catalytic subunit of cAMP-dependent protein kinase 3qbn Structure of Human Aurora A in Complex with a diaminopyrimidine 3qc4 PDK1 in complex with DFG-OUT inhibitor xxx 3qc9 Crystal structure of cross-linked bovine GRK1 T8C/N480C double mutant complexed with ADP and Mg 3qcq Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-(3-Amino-1H-indazol-6-yl)-N4-ethyl-2,4-pyrimidinediamine 3qcs Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-[2-Amino-6-(4-morpholinyl)-4-pyrimidinyl]-1H-indazol-3-amine 3qcx Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-{2-Amino-6-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl}-1H-indazol-3-amine 3qcy Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 4-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-N-phenyl-2-morpholinecarboxamide 3qd0 Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with (2R,5S)-1-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-N-phenyl-3-piperidinecarboxamide 3qd3 Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl {(3R,6S)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-3-piperidinyl}carbamate 3qd4 Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl{(3R,5R)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-5-methyl-3-piperidinyl}carbamate 3qf9 Crystal structure of human proto-oncogene serine threonine kinase (PIM1) in complex with a consensus peptide and a furan-thiazolidinedione ligand 3qfv MRCK beta in complex with TPCA-1 3qhr Structure of a pCDK2/CyclinA transition-state mimic 3qhw Structure of a pCDK2/CyclinA transition-state mimic 3qkk Spirochromane Akt Inhibitors 3qkl Spirochromane Akt Inhibitors 3qkm Spirocyclic sulfonamides as AKT inhibitors 3ql8 CDK2 in complex with inhibitor JWS-6-260 3qqf CDK2 in complex with inhibitor L1 3qqg CDK2 in complex with inhibitor L2-5 3qqh CDK2 in complex with inhibitor L2-2 3qqj CDK2 in complex with inhibitor L2 3qqk CDK2 in complex with inhibitor L4 3qql CDK2 in complex with inhibitor L3 3qrt CDK2 in complex with inhibitor NSK-MC2-55 3qru CDK2 in complex with inhibitor NSK-MC1-12 3qtq CDK2 in complex with inhibitor RC-1-137 3qtr CDK2 in complex with inhibitor RC-1-148 3qts CDK2 in complex with inhibitor RC-2-12 3qtu CDK2 in complex with inhibitor RC-2-132 3qtw CDK2 in complex with inhibitor RC-2-13 3qtx CDK2 in complex with inhibitor RC-2-35 3qtz CDK2 in complex with inhibitor RC-2-36 3qu0 CDK2 in complex with inhibitor RC-2-38 3qud Human p38 MAP Kinase in Complex with 2-amino-phenylamino-benzophenone 3que Human p38 MAP Kinase in Complex with Skepinone-L 3qwj CDK2 in complex with inhibitor KVR-1-142 3qwk CDK2 in complex with inhibitor KVR-1-150 3qx2 CDK2 in complex with inhibitor KVR-1-190 3qx4 CDK2 in complex with inhibitor KVR-1-78 3qxo CDK2 in complex with inhibitor KVR-1-84 3qxp CDK2 in complex with inhibitor RC-3-89 3qyw Crystal structure of ERK2 in complex with an inhibitor 3qyz Crystal structure of ERK2 in complex with an inhibitor 3qzf CDK2 in complex with inhibitor JWS-6-52 3qzg CDK2 in complex with inhibitor JWS-6-76 3qzh CDK2 in complex with inhibitor KVR-1-124 3qzi CDK2 in complex with inhibitor KVR-1-126 3r00 The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors 3r01 The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors 3r02 The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors 3r04 The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors 3r0t Crystal structure of human protein kinase CK2 alpha subunit in complex with the inhibitor CX-5279 3r1n MK3 kinase bound to Compound 5b 3r1q CDK2 in complex with inhibitor KVR-1-102 3r1s CDK2 in complex with inhibitor KVR-1-127 3r1y CDK2 in complex with inhibitor KVR-1-134 3r21 Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (Part I) 3r22 Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (Part I) 3r28 CDK2 in complex with inhibitor KVR-1-140 3r2b MK2 kinase bound to Compound 5b 3r2y MK2 kinase bound to Compound 1 3r30 MK2 kinase bound to Compound 2 3r63 Structure of ERK2 (SPE) mutant (S246E) 3r6x CDK2 in complex with inhibitor KVR-1-158 3r71 CDK2 in complex with inhibitor KVR-1-162 3r73 CDK2 in complex with inhibitor KVR-1-164 3r7e CDK2 in complex with inhibitor KVR-1-67 3r7i CDK2 in complex with inhibitor KVR-1-74 3r7u CDK2 in complex with inhibitor KVR-1-75 3r7v CDK2 in complex with inhibitor KVR-1-9 3r7y CDK2 in complex with inhibitor KVR-2-88 3r83 CDK2 in complex with inhibitor KVR-2-92 3r8l CDK2 in complex with inhibitor L3-4 3r8m CDK2 in complex with inhibitor L3-3 3r8p CDK2 in complex with inhibitor NSK-MC1-6 3r8u CDK2 in complex with inhibitor RC-1-132 3r8v CDK2 in complex with inhibitor RC-1-135 3r8z CDK2 in complex with inhibitor RC-1-136 3r9d CDK2 in complex with inhibitor RC-2-135 3r9h CDK2 in complex with inhibitor RC-2-142 3r9n CDK2 in complex with inhibitor RC-2-21 3r9o CDK2 in complex with inhibitor RC-2-143 3rah CDK2 in complex with inhibitor RC-2-22 3rai CDK2 in complex with inhibitor KVR-1-160 3rak CDK2 in complex with inhibitor RC-2-32 3ral CDK2 in complex with inhibitor RC-2-34 3raw Crystal Structure of human CDC-like kinase 3 isoform in complex with leucettine L41 3rcj Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling TMS-deprotection CuAAC sequence 3rgf Crystal Structure of human CDK8/CycC 3rin p38 kinase crystal structure in complex with small molecule inhibitor 3rjc CDK2 in complex with inhibitor L4-12 3rk5 CDK2 in complex with inhibitor RC-2-72 3rk7 CDK2 in complex with inhibitor RC-2-71 3rk9 CDK2 in complex with inhibitor RC-2-74 3rkb CDK2 in complex with inhibitor RC-2-73 3rm6 CDK2 in complex with inhibitor KVR-2-80 3rm7 CDK2 in complex with inhibitor KVR-1-91 3rmf CDK2 in complex with inhibitor RC-2-33 3rni CDK2 in complex with inhibitor RC-3-86 3rny Crystal structure of human RSK1 C-terminal kinase domain 3roc Crystal structure of human p38 alpha complexed with a pyrimidinone compound 3roy CDK2 in complex with inhibitor KVR-1-154 3rp9 Crystal Structure of the apo MapK from Toxoplasma Gondii, 25.m01780 or TGME49_007820 3rpo CDK2 in complex with inhibitor KVR-1-156 3rpr CDK2 in complex with inhibitor RC-2-49 3rps Structure of human CK2alpha in complex with the ATP-competitive inhibitor 3-(4,5,6,7-tetrabromo-1H-benzotriazol-1-yl)propan-1-ol 3rpv CDK2 in complex with inhibitor RC-2-88 3rpy CDK2 in complex with inhibitor RC-2-40 3rtp Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration 3rwp Discovery of a Novel, Potent and Selective Inhibitor of 3-Phosphoinositide Dependent Kinase (PDK1) 3rwq Discovery of a Novel, Potent and Selective Inhibitor of 3-Phosphoinositide Dependent Kinase (PDK1) 3rzb CDK2 in complex with inhibitor RC-2-23 3s00 CDK2 in complex with inhibitor L4-14 3s0o CDK2 in complex with inhibitor RC-1-138 3s1h CDK2 in complex with inhibitor RC-2-39 3s2p Crystal structure of CDK2 with a 2-aminopyrimidine compound 3s3i p38 kinase crystal structure in complex with small molecule inhibitor 3s4q P38 alpha kinase complexed with a pyrazolo-triazine based inhibitor 3sa0 Complex of ERK2 with norathyriol 3say Crystal structure of human glycogen synthase kinase 3 beta (GSK3b) in complex with inhibitor 142 3sc1 Novel Isoquinolone PDK1 Inhibitors Discovered through Fragment-Based Lead Discovery 3sd0 Identification of a Glycogen Synthase Kinase-3b Inhibitor that Attenuates Hyperactivity in CLOCK Mutant Mice 3she Novel ATP-competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series 3sls Crystal Structure of human MEK-1 kinase in complex with UCB1353770 and AMPPNP 3soa Full-length human CaMKII 3sqq CDK2 in complex with inhibitor RC-3-96 3sw4 Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor 3sw7 Crystal Structure of the CDK2 in complex with thiazolylpyrimidine inhibitor 3sx9 Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-132 3sxf Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-89 3t3u Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-130 3t3v Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with Bumped Kinase Inhibitor, RM-1-87 3t8o Rhodopsin kinase (GRK1) L166K mutant at 2.5A resolution 3t9i Pim1 complexed with a novel 3,6-disubstituted indole at 2.6 Ang Resolution 3tac Crystal Structure of the Liprin-alpha/CASK complex 3tei Crystal structure of human ERK2 complexed with a MAPK docking peptide 3tg1 Crystal structure of p38alpha in complex with a MAPK docking partner 3thb Structure of PLK1 kinase domain in complex with a benzolactam-derived inhibitor 3ti1 CDK2 in complex with SUNITINIB 3tiy CDK2 in complex with NSC 35676 3tiz CDK2 in complex with NSC 111848 3tkh Crystal structure of Chk1 in complex with inhibitor S01 3tki Crystal structure of Chk1 in complex with inhibitor S25 3tku MRCK beta in complex with fasudil 3tn8 CDK9/cyclin T in complex with CAN508 3tnh CDK9/cyclin T in complex with CAN508 3tni structure of CDK9/cyclin T F241L 3tnp Structure and Allostery of the PKA RIIb Tetrameric Holoenzyme 3tnq Structure and Allostery of the PKA RIIb Tetrameric Holoenzyme 3tnw Structure of CDK2/cyclin A in complex with CAN508 3tti Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitor 3ttj Crystal Structure of JNK3 complexed with CC-359, a JNK inhibitor for the prevention of ischemia-reperfusion injury 3tv7 Human Rho-associated protein kinase 1 (ROCK 1) in COMPLEX WITH RKI1342 3twj Rho-associated protein kinase 1 (ROCK 1) IN COMPLEX WITH RKI1447 3txo PKC eta kinase in complex with a naphthyridine 3u4u Casein kinase 2 in complex with AZ-Inhibitor 3u87 Structure of a chimeric construct of human CK2alpha and human CK2alpha' in complex with a non-hydrolysable ATP-analogue 3u8w Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Triazolopyridazinone inhibitor 3u9c Structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit with the ATP-competitive inhibitor resorufin 3u9n X-ray crystal structure of compound 1 bound to human CHK1 kinase domain 3ubd Structure of N-terminal domain of RSK2 kinase in complex with flavonoid glycoside SL0101 3uc3 The crystal structure of Snf1-related kinase 2.3 3uc4 The crystal structure of Snf1-related kinase 2.6 3udb Crystal structure of SnRK2.6 3uib Map kinase LMAMPK10 from leishmania major in complex with SB203580 3uix Crystal structure of Pim1 kinase in complex with small molecule inhibitor 3ujg Crystal structure of SnRK2.6 in complex with HAB1 3uli Human Cyclin Dependent Kinase 2 (CDK2) bound to azabenzimidazole derivative 3umw Crystal structure of Pim1 kinase in complex with inhibitor (Z)-2-[(1H-indazol-3-yl)methylene]-6-methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one 3umx Crystal structure of Pim1 kinase in complex with inhibitor (Z)-2-[(1H-indol-3-yl)methylene]-7-(azepan-1-ylmethyl)-6-hydroxybenzofuran-3(2H)-one 3unj CDK2 in complex with inhibitor YL1-038-31 3unk CDK2 in complex with inhibitor YL5-083 3unz Aurora A in Complex with RPM1679 3uo4 Aurora A in complex with RPM1680 3uo5 Aurora A in complex with YL1-038-31 3uo6 Aurora A in complex with YL5-083 3uod Aurora A in complex with RPM1693 3uoh Aurora A in complex with RPM1722 3uoj Aurora A in complex with RPM1715 3uok Aurora A in complex with YL5-81-1 3uol Aurora A in complex with SO2-162 3up2 Aurora A in complex with RPM1686 3up7 Aurora A in complex with YL1-038-09 3upx Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1300 3upz Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with bumpless BKI analog UW1243 3uto Twitchin kinase region from C.elegans (Fn31-NL-kin-CRD-Ig26) 3uvp Human p38 MAP Kinase in Complex with a Benzamide Substituted Benzosuberone 3uvq Human p38 MAP Kinase in Complex with a Dibenzosuberone Derivative 3uvr Human p38 MAP Kinase in Complex with KM064 3uzs Structure of the C13.28 RNA Aptamer Bound to the G Protein-Coupled Receptor Kinase 2-Heterotrimeric G Protein Beta 1 and Gamma 2 Subunit Complex 3uzt Structure of the C13.18 RNA Aptamer in Complex with G Protein-Coupled Receptor Kinase 2 3v01 Discovery of Novel Allosteric MEK Inhibitors Possessing Classical and Non-classical Bidentate Ser212 Interactions. 3v04 Discovery of Novel Allosteric MEK Inhibitors Possessing Classical and Non-classical Bidentate Ser212 Interactions. 3v3v Structural and functional analysis of quercetagetin, a natural JNK1 inhibitor 3v51 Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor RM-1-176 3v5p Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1288 3v5t Calcium-Dependent Protein Kinase 1 from Toxoplasma gondii (TgCDPK1) in complex with inhibitor UW1299 3v5w Human G Protein-Coupled Receptor Kinase 2 in Complex with Soluble Gbetagamma Subunits and Paroxetine 3v6r Discovery of potent and selective covalent inhibitors of JNK 3v6s Discovery of potent and selective covalent inhibitors of JNK 3v8s Human RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18) 3vap Synthesis and SAR Studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off target kinase selectivity 3vbq Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design 3vbt Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design 3vbv Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design 3vbw Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design 3vbx Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design 3vby Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design 3vc4 Exploitation of hydrogen bonding constraints and flat hydrophobic energy landscapes in Pim-1 kinase needle screening and inhibitor design 3vn9 Rifined Crystal structure of non-phosphorylated MAP2K6 in a putative auto-inhibition state 3vqh Bromine SAD partially resolves multiple binding modes for PKA inhibitor H-89 3vqu CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-[(4-amino-5-cyano-6-ethoxypyridin-2- yl)amino]benzamide 3vud Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1 3vug Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1 3vuh Crystal structure of a cysteine-deficient mutant M3 in MAP kinase JNK1 3vui Crystal structure of a cysteine-deficient mutant M2 in MAP kinase JNK1 3vuk Crystal structure of a cysteine-deficient mutant M5 in MAP kinase JNK1 3vul Crystal structure of a cysteine-deficient mutant M1 in MAP kinase JNK1 3vum Crystal structure of a cysteine-deficient mutant M7 in MAP kinase JNK1 3vut Crystal structures of non-phosphorylated MAP2K4 3vvh X-ray structure of the human mitogen-activated protein kinase kinase 1 (MEK1) in complex with an inhibitor and MgATP 3vw6 Crystal structure of human apoptosis signal-regulating kinase 1 (ASK1) with imidazopyridine inhibitor 3w10 Aurora kinase A complexed to pyrazole aminoquinoline I 3w16 Structure of Aurora kinase A complexed to pyrazole-aminoquinoline inhibitor III 3w18 Structure of Aurora kinase A complexed to benzoimidazole-indazole inhibitor XIII 3w1f Crystal structure of Human MPS1 catalytic domain in complex with 5-(5-ethoxy-6-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl)-2-methylbenzenesulfonamide 3w2c Structure of Aurora kinase A complexed to benzoimidazole-indazole inhibitor XV 3w55 The structure of ERK2 in complex with FR148083 3w8l Crystal structure of human CK2 in complex with inositol hexakisphosphate 3w8q Structure of the Human Mitogen-Activated Protein Kinase Kinase 1 (MEK1) 3war Crystal structure of human CK2a 3wbl Crystal structure of CDK2 in complex with pyrazolopyrimidine inhibitor 3we4 3WE4 3we8 Pim-1 kinase in complex with Ruthenium-based inhibitor 3wf5 3WF5 3wf6 3WF6 3wf7 3WF7 3wf8 3WF8 3wf9 3WF9 3wi6 Crystal structure of MAPKAP Kinase-2 (MK2) in complex with non-selective inhibitor 3wig 3WIG 3wik 3WIK 3wil 3WIL 3wow 3WOW 3wyx 3WYX 3wyy 3WYY 3wzj 3WZJ 3wzk 3WZK 3wzu 3WZU 3x2u 3X2U 3x2v 3X2V 3x2w 3X2W 3zdi Glycogen Synthase Kinase 3 Beta complexed with Axin Peptide and Inhibitor 7d 3zdu Crystal structure of the human CDKL3 kinase domain 3zh8 A novel small molecule aPKC inhibitor 3zhp Human MST3 (STK24) in complex with MO25beta 3zls Crystal structure of MEK1 in complex with fragment 6 3zlw Crystal structure of MEK1 in complex with fragment 3 3zlx Crystal structure of MEK1 in complex with fragment 18 3zly Crystal structure of MEK1 in complex with fragment 8 3zm4 Crystal structure of MEK1 in complex with fragment 1 3zo1 The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors 3zo2 The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors 3zo3 The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors 3zo4 The Synthesis and Evaluation of Diazaspirocyclic Protein Kinase Inhibitors 3zrk Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors 3zrl Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors 3zrm Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors 3zs5 Structural basis for kinase selectivity of three clinical p38alpha inhibitors 3zsg X-ray structure of p38alpha bound to TAK-715 3zsh X-ray structure of p38alpha bound to SCIO-469 3zsi X-ray structure of p38alpha bound to VX-745 3ztx Aurora kinase selective inhibitors identified using a Taxol-induced checkpoint sensitivity screen. 3zu7 Crystal structure of a designed selected Ankyrin Repeat protein in complex with the MAP kinase ERK2 3zut The structure of OST1 (D160A) kinase 3zuu The structure of OST1 (D160A, S175D) kinase in complex with gold 3zuv Crystal structure of a designed selected Ankyrin Repeat protein in complex with the phosphorylated MAP kinase ERK2 3zxt Dimeric structure of DAPK-1 catalytic domain in complex with AMPPCP- Mg 3zya Human p38 MAP Kinase in Complex with 2-amino-phenylamino- dibenzosuberone 4a06 Human PDK1 Kinase Domain in Complex with Allosteric Activator PS114 Bound to the PIF-Pocket 4a07 Human PDK1 Kinase Domain in Complex with Allosteric Activator PS171 Bound to the PIF-Pocket 4a4l CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO- PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR 4a4o CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2-(2-AMINO- PYRIMIDIN-4-YL)-1,5,6,7-TETRAHYDRO-PYRROLOPYRIDIN-4-ONE INHIBITOR 4a4x NEK2-EDE bound to CCT248662 4a7c Crystal structure of PIM1 kinase with ETP46546 4a9r CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR 4a9s CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR 4a9t CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR 4a9u CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR 4a9y P38ALPHA MAP KINASE BOUND TO CMPD 8 4aa0 P38ALPHA MAP KINASE BOUND TO CMPD 2 4aa4 P38ALPHA MAP KINASE BOUND TO CMPD 22 4aa5 P38ALPHA MAP KINASE BOUND TO CMPD 33 4aaa Crystal structure of the human CDKL2 kinase domain 4aac P38ALPHA MAP KINASE BOUND TO CMPD 29 4acc GSK3b in complex with inhibitor 4acd GSK3b in complex with inhibitor 4acg GSK3b in complex with inhibitor 4ach GSK3b in complex with inhibitor 4acm CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL]SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE 4ae6 A Crystal Structure of the Sperm Specific Isoform of Protein Kinase A (PKA) Subunit CalphaS Reveals a Binding Pocket for Hydrophobic Moieties 4ae9 A Crystal Structure of the Sperm Specific Isoform of Protein Kinase A (PKA) Subunit CalphaS Reveals a Binding Pocket for Hydrophobic Moieties 4af3 Human Aurora B Kinase in complex with INCENP and VX-680 4afe Nek2 bound to hybrid compound 21 4afj 5-aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors 4agu CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN 4alu Benzofuropyrimidinone Inhibitors of Pim-1 4alv Benzofuropyrimidinone Inhibitors of Pim-1 4alw Benzofuropyrimidinone Inhibitors of Pim-1 4an2 Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs. 4an3 Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs. 4an9 Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs. 4anb Crystal structures of human MEK1 with carboxamide-based allosteric inhibitor XL518 (GDC-0973), or related analogs. 4anm Complex of CK2 with a CDC7 inhibitor 4aot Crystal Structure of Human Serine Threonine Kinase-10 (LOK) Bound to GW830263A 4apc Crystal Structure of Human NIMA-related Kinase 1 (NEK1) 4app Crystal Structure of the Human p21-Activated Kinase 4 in Complex with (S)-N-(5-(3-benzyl-1-methylpiperazine-4-carbonyl)-6,6-dimethyl-1,4,5, 6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-phenoxybenzamide 4ark CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH A SMALL MOLECULE INHIBITOR AND ADP 4as0 Cyclometalated Phthalimides as Protein Kinase Inhibitors 4au8 Crystal structure of compound 4a in complex with cdk5, showing an unusual binding mode to the hinge region via a water molecule 4aua Liganded X-ray crystal structure of cyclin dependent kinase 6 (CDK6) 4aw0 Human PDK1 Kinase Domain in Complex with Allosteric Compound PS182 Bound to the PIF-Pocket 4aw1 Human PDK1 Kinase Domain in Complex with Allosteric Compound PS210 Bound to the PIF-Pocket 4aw2 Crystal structure of CDC42 binding protein kinase alpha (MRCK alpha) 4awi Human Jnk1alpha kinase with 4-phenyl-7-azaindole IKK2 inhibitor. 4axa Structure of PKA-PKB chimera complexed with (1S)-2-amino-1-(4- chlorophenyl)-1-(4-(1H-pyrazol-4-yl)phenyl)ethan-1-ol 4aze Human DYRK1A in complex with Leucettine L41 4azf Human DYRK2 in complex with Leucettine L41 4b0g Complex of Aurora-A bound to an Imidazopyridine-based inhibitor 4b4l CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT 4b6l Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design 4b7t Glycogen Synthase Kinase 3 Beta complexed with Axin Peptide and Leucettine L4 4b8l Aurora B kinase P353G mutant 4b8m Aurora B kinase in complex with VX-680 4b99 Crystal Structure of MAPK7 (ERK5) with inhibitor 4b9d Crystal Structure of Human NIMA-related Kinase 1 (NEK1) with inhibitor. 4bbm CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312 4bc6 Crystal structure of human serine threonine kinase-10 bound to novel Bosutinib Isoform 1, previously thought to be Bosutinib 4bcf Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bcg Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bch Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bci Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bcj Structure of CDK9 in complex with cyclin T and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bck Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bcm Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bcn Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bco Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bcp Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bcq Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 4bda Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdb Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdc Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdd Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bde Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdf Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdg Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdh Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdi Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdj Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bdk Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2) 4bf2 Crystal Structures of Ask1-inhibitor Complexes 4bfm The crystal structure of mouse PK38 4bgh Crystal Structure of CDK2 in complex with pan-CDK Inhibitor 4bgq Crystal structure of the human CDKL5 kinase domain 4bhn Crystal Structures of Ask1-inhibitor Complexes 4bhz Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor 4bi0 Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor 4bi1 Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor 4bi2 Scaffold Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitor 4bib Crystal Structures of Ask1-inhibitor Complexes 4bic Crystal Structures of Ask1-inhibitor Complexes 4bid Crystal Structures of Ask1-inhibitor Complexes 4bie Crystal Structures of Ask1-inhibitor Complexes 4bky Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with pyrrolopyrazole inhibitor 4bkz Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with a benzodipyrazole inhibitor 4bl1 Crystal structure of unphosphorylated Maternal Embryonic Leucine zipper Kinase (MELK) in complex with AMP-PNP 4bn1 Crystal structure of V174M mutant of Aurora-A kinase 4byi Aurora A kinase bound to a highly selective imidazopyridine inhibitor 4byj Aurora A kinase bound to a highly selective imidazopyridine inhibitor 4bzd 4BZD 4bzn Crystal structure of PIM1 in complex with a Pyrrolo(1,2-a)Pyrazinone inhibitor 4bzo Crystal structure of PIM1 in complex with a Pyrrolo-Pyrazinone inhibitor 4c0t Candida albicans PKh Kinase Domain 4c2v Aurora B kinase in complex with the specific inhibitor Barasertib 4c2w Crystal structure of Aurora B in complex with AMP-PNP 4c33 PKA-S6K1 Chimera Apo 4c34 PKA-S6K1 Chimera with Staurosporine bound 4c35 PKA-S6K1 Chimera with compound 1 (NU1085) bound 4c36 PKA-S6K1 Chimera with compound 15e (CCT147581) bound 4c37 PKA-S6K1 Chimera with compound 21a (CCT196539) bound 4c38 PKA-S6K1 Chimera with compound 21e (CCT239066) bound 4c3p 4C3P 4c3r 4C3R 4c4e Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 4c4f Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 4c4g Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 4c4h Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1